

CA SUBSCRIBER PRICE

0.00

-82.19

FILE 'REGISTRY' ENTERED AT 12:48:02 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3
DICTIONARY FILE UPDATES: 30 APR 2002 HIGHEST RN 409303-45-3


TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d l31 que stat;d 1-119 ide cbib abs;fil caplus;s l31
L1 STR



VAR G1=NH2/18/16

REP G2=(1-6) 20

VAR G3=23/27

VAR G4=H/C

VAR G5=H/ME

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29







STEREO ATTRIBUTES: NONE

L3 10 SEA FILE=REGISTRY SSS FUL L1

L21 SCR 1842

L24 STR

Searched by: Mary Hale 308-4258 CM-1 12D16



VAR G1=NH2/18/16
VAR G2=36/37/38-12 39-31/CY
VAR G3=23/27
VAR G4=H/C
VAR G5=H/ME
VAR G6=36/37/38-31 39-33/CY
VAR G7=36/37/38-33 39-35/CY
REP G8=(0-3) C

NODE ATTRIBUTES:

NSPEC IS RC AT 36

NSPEC IS RC AT 37

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

L26 STR




VAR G1=O/C
VAR G2=H/P/10
VPA 6-3/2/1/5 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L28 241 SEA FILE=REGISTRY SSS FUL L24 NOT L26
L29 122 SEA FILE=REGISTRY SUB=L28 SSS FUL L21
L30 119 SEA FILE=REGISTRY ABB=ON PLU=ON L28 NOT L29
L31 119 SEA FILE=REGISTRY ABB=ON PLU=ON L30 NOT L3

L31 ANSWER 1 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 272461-63-9 REGISTRY
CN .beta.-D-Glucopyranosiduronic acid, [(2R,5S)-5-(6-amino-9H-purin-9-yl)tetrahydro-2-furanyl]methyl (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H21 N5 O8
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


Searched by: Mary Hale 308-4258 CM-1 12D16

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:12325 Intracellular metabolism of .beta.-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activity. Placidi, Laurent; Cretton-Scott, Erika; Gosselin, Gilles; Pierra, Claire; Schinazi, Raymond F.; Imbach, Jean-Louis; El Kouni, Mahmoud H.; Sommadossi, Jean-Pierre (Department of Pharmacology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA). Antimicrobial Agents and Chemotherapy, 44(4), 853-858 (English) 2000. CODEN: AMACCQ. ISSN: 0066-4804. Publisher: American Society for Microbiology.

AB The intracellular metab. of the .beta.-L-enantiomer of 2',3'-dideoxyadenosine (.beta.-L-ddA) was investigated in HepG2 cells, human peripheral blood mononuclear cells (PBMC), and primary cultured human hepatocytes in an effort to understand the metabolic basis of its limited activity on the replication of human immunodeficiency virus and hepatitis B virus. Incubation of cells with 10 .mu.M [2',3',8-3H]-.beta.-L-ddA resulted in an increased intracellular concn. of .beta.-L-ddA with time, demonstrating that these cells were able to transport .beta.-L-ddA. However, it did not result in the phosphorylation of .beta.-L-ddA to its pharmacol. active 5'-triphosphate (.beta.-L-ddATP). Five other intracellular metabolites were detected and identified as .beta.-L-2',3'-dideoxyribonolactone, hypoxanthine, inosine, ADP, and ATP, with the last being the predominant metabolite, reaching levels as high as 5.14, 8.15, and 15.60 pmol/106 cells at 8, 4, and 2 h in HepG2 cells, PBMC, and hepatocytes, resp. In addn., a .beta.-glucuronic deriv. of .beta.-L-ddA was detected in cultured hepatocytes, accounting for 12.5% of the total metabolite pool. Coincubation of hepatocytes in primary culture with .beta.-L-ddA in the presence of increasing concns. of 5'-methylthioadenosine resulted in decreased phosphorolysis of .beta.-L-ddA and formation of assocd. metabolites. These results indicate that the limited antiviral activity of .beta.-L-ddA is the result of its inadequate phosphorylation to the nucleotide level due to phosphorolysis and catabolism of .beta.-L-ddA by methylthioadenosine phosphorylase (EC 2.4.2.28).

L31 ANSWER 2 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 263765-23-7 REGISTRY
CN Carbamic acid, [3-[[2-(6-amino-9H-purin-9-yl)ethyl]amino]-3-oxopropyl][3-[[[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H38 N8 O5
SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:279180 Synthesis and study of a new adenine-acridine tandem, inhibitor of exonuclease III. Belmont, Philippe; Demeunynck, Martine; Constant, Jean-Francois; Lhomme, Jean (LEDSS, Chimie Bioorganique, UMR CNRS 5616, LEDSS, Chimie Bioorganique, UMR CNRS 5616, Universite Joseph Fourier, Grenoble, 38041, Fr.). Bioorganic & Medicinal Chemistry Letters, 10(3), 293-295 (English) 2000. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..


GI



AB A new heterodimer adenine-chain-acridine (I), contg. a mixed amido-guanidinium linker chain, was synthesized. To achieve the synthesis, a new method of introduction of the aminoalkyl chain at position 9 of adenine was designed. The heterodimer interacts specifically with the abasic sites in DNA and inhibits the major base excision repair enzyme in Escherichia coli, exonuclease III.

L31 ANSWER 3 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 253779-46-3 REGISTRY
 CN Adenosine, 5'-deoxy-5'-[[[(1,1-dimethylethoxy)carbonyl] [(phenylmethoxy)carbonyl]oxy]amino]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H28 N6 O8
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:78796 Syntheses of 5'-Deoxy-5'-N-hydroxylaminopyrimidine and Purine Nucleosides: Building Blocks for Novel Antisense Oligonucleosides with Hydroxamate Linkages. Li, Hui; Miller, Marvin J. (Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA). Journal of Organic Chemistry, 64(25), 9289-9293 (English) 1999. CODEN: JOCEAH. ISSN: 0022-3263. Publisher: American Chemical Society.

AB A general and efficient route for the conversion of the 5'-hydroxyl group of a nucleoside into the corresponding 5'-N-hydroxylamino-substituted derivs. is described. The key step involves the Mitsunobu reaction of the nucleoside with the bis-protected hydroxylamine, N-(t-butoxycarbonyl)-O-(benzyloxycarbonyl)hydroxylamine.

L31 ANSWER 4 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 249550-90-1 REGISTRY

CN Adenosine, 5'-deoxy-5'-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-methoxy-4-oxobutyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C24 H37 N7 O7

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 131:322879 Synthesis of Two Stable Nitrogen Analogs of S-Adenosyl-L-methionine. Thompson, Mark J.; Mekhelfia, Abdelaziz; Hornby, David P.; Blackburn, G. Michael (Krebs Institute Departments of Chemistry and Molecular Biology, University of Sheffield, Brook Hill Sheffield, S3 7HF, UK). Journal of Organic Chemistry, 64(20), 7467-7473 (English) 1999. CODEN: JOCEAH. ISSN: 0022-3263. Publisher: American Chemical Society.


AB Homochiral syntheses of two stable nitrogen analogs of S-adenosyl-L-methionine (AdoMet) are described. In the first analog, AzaAdoMet, the sulfonium center of AdoMet, is replaced by an N-Me moiety whose pKa is 7.08. This provides a charge-switchable analog of AdoMet whose ionic state is a function of the pH. A second analog, MeAzaAdoMet, has a quaternary dimethyl-ammonium group in place of the methyl-sulfonium

Searched by: Mary Hale 308-4258 CM-1 12D16

center of AdoMet: thus, its ionic state is independent of pH.

L31 ANSWER 5 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 221896-26-0 REGISTRY
CN 5-Oxa-7,11,15-triaza-2-silahexadecane-16-oic acid, 15-[2-(6-amino-9H-purin-9-yl)ethyl]-2,2-dimethyl-6-oxo-11-[[2-(trimethylsilyl)ethoxy]carbonyl]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H60 N8 O6 Si3
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



— SiMe₃

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:267260 Synthesis of an imidazo[1,2-e]purine-acridine heterodimer for targeting abasic sites in DNA. Belmont, Philippe; Alarcon, Karine; Demeunynck, Martine; Lhomme, Jean (LEDSS, UMR CNRS 5616/Universite J. Fourier; Grenoble, 38041, Fr.). Bioorg. Med. Chem. Lett., 9(2), 233-236 (English) 1999. CODEN: BMCLE8. ISSN: 0960-894X. Publisher: Elsevier Science Ltd..


GI



AB Cyclization of 8-bromo-9-[(alkylamino)ethyl]adenine I quant. affords a substituted imidazo[1,2-e]purine II. The corresponding heterodimer, imidazo[1,2-e]purine-acridine, was prepd. and its interaction with abasic site contg. oligonucleotides was studied.

L31 ANSWER 6 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 182126-62-1 REGISTRY
 CN Adenosine, 2'-deoxy-, 5'-(ethenyl dicarbonate) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C14 H15 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 125:248307 Synthesis of Purine and Pyrimidine
 3'-Amino-3'-deoxy- and 3'-Amino-2',3'-dideoxyxylonucleosides.
 Garcia-Alles, Luis F.; Magdalena, Julia; Gotor, Vicente (Facultad de
 Quimica, Universidad de Oviedo, Oviedo, 33071, Spain). J. Org. Chem.,
 61(20), 6980-6986 (English) 1996. CODEN: JOCEAH. ISSN: 0022-3263.

GI


Searched by: Mary Hale 308-4258 CM-1 12D16



AB A general procedure to obtain the 3'-aminodeoxyxylonucleosides, e.g. I (B = adenine, uridine), is presented. The synthetic scheme is based on the 5' directed intramol. nucleophilic substitution at the 3'-activated position of the nucleoside. The approach of the incoming group to this position takes place regio- and stereoselectively from the most hindered face of the nucleoside. The methodol. presented is applicable to ribonucleosides and 2'-deoxyribonucleosides, regardless of their nitrogenated base.

L31 ANSWER 7 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 172487-62-6 REGISTRY
 CN Carbamic acid, [2-[[6-(6-amino-9H-purin-9-yl)tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [3aS-[3a.alpha.,4.beta.(R*),6.beta.,6a.alpha.]]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H31 N7 O5
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:87644 Synthesis of enantiomerically pure 5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller, Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH. ISSN: 0022-3263.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16




I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.

L31 ANSWER 8 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 172487-61-5 REGISTRY
 CN Carbamic acid, [2-[[4-(6-amino-9H-purin-9-yl)-2,3-dihydroxycyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1S-[1.alpha.(R*),2.alpha.,3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H27 N7 O5
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:87644 Synthesis of enantiomerically pure

Searched by: Mary Hale 308-4258 CM-1 12D16

5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller, Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH. ISSN: 0022-3263.

GI



I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.

L31 ANSWER 9 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 172323-71-6 REGISTRY

CN Carbamic acid, [2-[[6-(6-amino-9H-purin-9-yl)tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [3aR-[3a.alpha.,4.alpha.(S*),6.alpha.,6a.alpha.]]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C21 H31 N7 O5

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

REFERENCE 1: 124:87644 Synthesis of enantiomerically pure
5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller,
Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556,
USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH.
ISSN: 0022-3263.

GI



I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins,
e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed
addn. of the sodium salt of adenine, and catalytic osmium tetroxide
dihydroxylation, is described.

L31 ANSWER 10 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 172323-70-5 REGISTRY

CN Carbamic acid, [(1S)-2-[[[(1S,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)-2,3-
dihydroxycyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Carbamic acid, [2-[[[4-(6-amino-9H-purin-9-yl)-2,3-
dihydroxycyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl
ester, [1S-[1.alpha.(R*),2.beta.,3.beta.,4.alpha.]]-


FS STEREOSEARCH

MF C18 H27 N7 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:237791 Synthesis and biological evaluation of a carbocyclic azanoraristeromycin siderophore conjugate. Ghosh, Arun; Miller, Marvin J.; De Clercq, Erik; Balzarini, Jan (Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA). Nucleosides Nucleotides, 18(2), 217-225 (English) 1999. CODEN: NUNUD5. ISSN: 0732-8311. Publisher: Marcel Dekker, Inc..


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Synthesis and biol. evaluation of a carbocyclic azanoraristeromycin siderophore conjugate (I) is reported. Coupling of previously prepd. L-alanyl-4'-azanoraristeromycin (II) with protected tripeptide tri-hydroxamate, followed by hydrogenolytic removal of all protecting groups, provided the first carbocyclic azanoraristeromycin siderophore conjugate I. Compds. I and II showed inhibitory activity against tumor cells, and conjugate I, in particular, displayed significant activity against those viruses (i.e. reo, parainfluenza, vaccinia, cytomegalo) that are known to be inhibited by S-adenosyl-homocysteine hydrolase inhibitors.

REFERENCE 2: 124:87644 Synthesis of enantiomerically pure 5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller, Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH. ISSN: 0022-3263.

GI



I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.

L31 ANSWER 11 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 172323-69-2 REGISTRY

CN Carbamic acid, [2-[[3-(6-amino-9H-purin-9-yl)cyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1R-[1.alpha.(S*),3.alpha.]]- (9CI)
(CA INDEX NAME)


FS STEREOSEARCH

MF C18 H27 N7 O3

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:87644 Synthesis of enantiomerically pure 5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller, Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH. ISSN: 0022-3263.

GI



I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.

L31 ANSWER 12 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 172323-67-0 REGISTRY

CN Carbamic acid, [2-[[4-(6-amino-9H-purin-9-yl)-2-cyclopenten-1-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1S-[1.alpha.(R*),4.alpha.]]-(9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C18 H25 N7 O3

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 124:87644 Synthesis of enantiomerically pure 5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller, Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA). J. Org. Chem., 60(18), 5808-13 (English) 1995. CODEN: JOCEAH. ISSN: 0022-3263.

GI



AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.

L31 ANSWER 13 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 155177-51-8 REGISTRY
 CN .beta.-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-.beta.-alanyl-N-[3-(6-amino-9H-purin-9-yl)propyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H30 N8 O4
 SR CA
 LC STN Files: CA, CAPLUS





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 120:323064 Synthesis of purine-acridine hybrid molecules related to artificial endonucleases. Fkyerat, Abdellatif; Demeunynck, Martine; Constant, Jean Francois; Lhomme, Jean (Univ. J. Fourier, Grenoble, 38041, Fr.). Tetrahedron, 49(48), 11237-52 (English) 1993. CODEN: TETRAB. ISSN: 0040-4020.


GI



AB In the course of a program devoted to the synthesis of artificial endonucleases, the hybrid mols. I ($R = H, NH_2$, $n = 1, 2$) and II ($X = COCH_2CH_2, CH_2CH_2CO$) in which a purine is linked to an aminoacridine by an aliph. chain contg. amido or/and amino groups have been prepd. The key intermediates are .alpha.-halo-.omega.-amino polyaza chains which may be of general use as linkers in bioconjugate chem. I and II recognize and cleave selectively abasic sites in DNA with very high efficiency.

L31 ANSWER 14 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 152918-10-0 REGISTRY
 CN Carbamic acid, [2-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-.beta.-D-ribofuranuronoyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H25 N7 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:109311 Preparation of nucleoside uronamides as A3 adenosine receptor agonists. Jacobson, Kenneth A.; Gallo-Rodriguez, Carola; Van Galen, Philip J. M.; Von Lubitz, Dag K. J. E.; Jeong, Heaok Kim (United States Dept. of Health and Human Services, USA). U.S. US 5773423 A 19980630, 54 pp. Cont.-in-part of U. S. Ser. No. 163,324, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1994-274628 19940713. PRIORITY: US 1993-91109 19930713; US 1993-163324 19931206.

GI



AB The present invention provides N6-benzyladenosine-5'-N-uronamide and related substituted compds. I (R1 = amide; R2 = halo, amino, alkenyl, alkynyl, thio, alkylthio; R3 = S-1-phenylethyl, Bn, phenylethyl), particularly those contg. substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compns. contg. such compds. The present invention also provides a method of selectively activating an A3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A3 adenosine receptor a therapeutically effective amt. of a compd. which binds with the A3 receptor so as to stimulate an A3 receptor-dependent response. Thus, N6-(3-iodobenzyl)adenosine was prepd. tested for its affinity in binding at rat brain A1, A2, A3 adenosine receptors (K_i = 9.5-220.0 nM).


REFERENCE 2: 124:225 Comparative molecular field analysis of selective A3 adenosine receptor agonists. Siddiqi, Suhaib M.; Pearlstein, Robert A.; Sanders, Lawrence H.; Jacobson, Kenneth A. (Molecular Recognition Section, Lab. Bioorganic Chem., Bethesda, MD, 2082, USA). Bioorg. Med. Chem., 3(10), 1331-43 (English) 1995. CODEN: BMECEP. ISSN: 0968-0896.

AB A series of 48 N6-benzyladenosine 5'-uronamide derivs. has been described recently as moderately selective A3 adenosine receptor agonists of nanomolar potency (Gallo-Rodriguez, C. et al. J. Med. Chem. 1994, 37, 636). Quant. structure activity relationships in this series, including some novel derivs., have been investigated using a Comparative Mol. Field Anal. (CoMFA), with emphasis on the N6-substituent. The resulting three-dimensional pharmacophore model defines the steric and electronic factors which modulate in vitro affinities in binding to rat brain A3 adenosine receptors. The model indicates a pos. correlation of affinity with the steric characteristics of the compds. (major factor),

particularly toward the 3-position of the benzyl ring of N6-benzyl NECA, and a weak correlation with the electrostatic effects of the N6-substituent. A comparison of active and inactive compds. using vol. maps showed that bulk at the 3-position of the benzyl ring of the mol. is conducive to high affinity at A3 receptors, while steric bulk at other positions of the benzyl ring leads to poor binding. T-Boc-amino acid conjugates of a 3-aminobenzyl deriv. were synthesized to probe the steric and hydrophobic limitations at that position. We have discovered a subregion of the N6-benzyl binding pocket occupied by a 3-(L-prolylamino) group that is sterically disallowed at A3 receptors and allowed in A1 and A2 receptors. 6-N-Phenylhydrazino and 6-O-phenylhydroxylamino derivs., incorporating major changes in electrostatic character of the ligand proximal to the purine, were predicted by the CoMFA model to have high A3 affinity. Such analogs were synthesized and found to be well tolerated at the A3 receptor binding site.

REFERENCE 3: 123:257265 Preparation of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compounds as adenosine A3 receptor agonists.. Jacobson, Kenneth A.; Gallo-Rodriguez, Carola; Von Galen, Philip J. M.; Von Lubitz, Dag K. J. E.; Jeong, Heaok Kim (United States Dept. of Health and Human Services, USA). PCT Int. Appl. WO 9502604 A1 19950126, 175 pp. DESIGNATED STATES: W: AU, CA, JP; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1994-US7835 19940713. PRIORITY: US 1993-91109 19930713; US 1993-163324 19931206.

GI



I

AB Title compds. [I; R¹ = RaRbNCO, HORc; Ra, Rb = H, alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; RaRbN = heterocyclyl; Rc = alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; R² = H, halo, alkyl ether residue, amino, alkylamino, alkenyl, alkynyl, thio, alkylthio; R³ = (R)- and (S)-1-phenylethyl, (substituted) PhCH₂, substituted phenylethyl] and related compds., were prepd. Thus, 2-chloro-N6-(3-iodobenzyl)adenine was refluxed with hexamethyldisilazane and cat. (NH₄)₂SO₄ to give a silyl deriv. which was refluxed with N-Me I-O-acetyl-2,3-dibenzoyl-.alpha.,.beta.-D-ribofuronamide and trimethylsilyl triflate in dichloroethane to give 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-2,3-di-O-benzoyl-.beta.-D-ribofuranosyl]adenine. The latter was stirred with NH₃ in MeOH for 16 h to give 68.7% 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-.beta.-D-ribofuranosyl]adenine. This showed K_i = 0.23 nM in a radioligand binding assay at rat brain A3 receptors.

REFERENCE 4: 120:289415 Structure-Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists.

Searched by: Mary Hale 308-4258 CM-1 12D16

Gallo-Rodriguez, Carola; Ji, Xiao-duo; Melman, Neli; Siegman, Barry D.; Sanders, Lawrence H.; Orlina, Jeraldine; Fischer, Bilha; Pu, Quanlong; Olah, Mark E.; et al. (Laboratory of Bioorganic Chemistry, National Institute of Diabetes Digestive Kidney Diabetes, Bethesda, MD, 20892, USA). J. Med. Chem., 37(5), 636-46 (English) 1994. CODEN: JMCMAR. ISSN: 0022-2623.

AB Adenosine analogs modified at the 5'-position as uronamides and/or as N6-benzyl derivs. were synthesized. These derivs. were examd. for affinity in radioligand binding assays at the newly discovered rat brain A3 adenosine receptor and at rat brain A1 and A2a receptors. 5'-Uronamide substituents favored A3 selectivity in the order N-Me > N-Et .apprx. unsubstituted carboxamide > N-cyclopropyl. 5'-N-Methyl-N6-benzyladenosine was 37-56-fold more selective for A3 receptors. Potency at A3 receptors was enhanced upon substitution of the benzyl substituent with nitro and other groups. 5'-N-Methyluronamides and N6-(3-substituted-benzyl)adenosines are optimal for potency and selectivity at A3 receptors. A series of 3-(halobenzyl)-5'-N-ethyluronamide derivs. showed the order of potency at A1 and A2a receptors of I .apprx. Br > Cl > F. At A3 receptors the 3-F deriv. was weaker than the other halo derivs. 5'-N-Methyl-N6-(3-iodobenzyl)adenosine displayed a Ki value of 1.1 nM at A3 receptors and selectivity vs. A1 and A2a receptors of 50-fold. A series of methoxybenzyl derivs. showed that a 4-methoxy group best favored A3 selectivity. A 4-sulfobenzyl deriv. was a specific ligand at A3 receptors of moderate potency. An aryl amino deriv. was prepd. as a probe for radioiodination and receptor crosslinking.

L31 ANSWER 15 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 128490-36-8 REGISTRY

CN Adenosine, 5'-deoxy-5'-[[5-(1,1-dimethylethoxy)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxo-2-pentenyl]methylamino]-2',3'-O-(1-methylethylidene)-, (Z)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Furo[3,4-d]-1,3-dioxole, adenosine deriv.

FS STEREOSEARCH


MF C28 H43 N7 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:78901 Preparation of 5'-deoxy-5'-aminoadenosine derivatives as S-adenosylmethionine decarboxylase inhibitors. Casara, Patrick; Danzin, Charles (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 351475 A1 19900124, 20 pp. DESIGNATED STATES: R: FR. (English). CODEN: EPXXDW. APPLICATION: EP 1988-401896 19880721.

GI



AB The title compds. [I; R = NR₁ZNH₂; R₁ = H, Me, Et; Z = CV1V2C(:CXY)CH₂, CV1V2C.tplbond.CCH₂, Q, cis-CV1V2CW:CZ1CH, CV1V2CR2FCH₂, CH₂CH₂CWZ1CH₂; R₂ = H, F; n = 1, 2; V₁ = H, Me; V₂ = H, CO₂H; W, X, Y, Z = H, F, Cl, Br] are prepd. I are potent and irreversible inhibitors of S-adenosylmethionine decarboxylase, and therefore significantly interfere with the formation of spermine and spermidine, and are useful for treatment of diseases assocd. with the rapid proliferation of normal and transformed cells (no data). I in combination with an ornithine decarboxylase (ODC) inhibitor are useful as postcoital contraceptives and menstruation inducers. Antitumor agents in conjunction with I lower side effects and increase survival time. I alone or in combination with an ODC inhibitor may be used as parasiticides, bactericides, fungicides or virucides. Thus, a soln. of cis-Me₃CO₂CNHCH₂CH:CHCH₂Cl, 5'-deoxy-5'-methylamino-2',3'-isopropylideneadenosine, K₂CO₃, and NaI in MeCN was refluxed overnight to give, after hydrolysis with 1N aq. H₂SO₄, I (R = cis-H₂NCH₂CH:CHCH₂NMe). A total of 9 I were prepd.

L31 ANSWER 16 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 128490-31-3 REGISTRY

CN Adenosine, 5'-deoxy-5'-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-difluoropropyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Furo[3,4-d]-1,3-dioxole, adenosine deriv.

FS STEREOSEARCH


MF C22 H33 F2 N7 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:70267 Preparation of 5-amino group-containing adenosine analogs as immunosuppressants.. Bowlin, Terry L. (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 472181 A2 19920226, 28 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1991-113994 19910821. PRIORITY: US 1990-571042 19900822.

GI




I

AB The title compds. [I; R = H, Me, Et; Q = (substituted) amino-2-butenyl, (substituted) aminopropyl, (substituted) butynyl, (substituted) aminofluoropropyl, (substituted) aminobutyl, etc.;. cis-N-tert-Butoxycarbonyl-4-chloro-2-butenylamine (prepn. given) was refluxed with 5'-deoxy-5'-(methylamino)-2',3'-isopropylideneadenosine in MeCN contg. K2CO3 and NaI overnight to give, after deprotection (H2SO4 at room temp. for 2 days), cis-5'-deoxy-5'-(4-amino-2-butenyl)methylaminoadenosine. This at 100 .mu.M showed 64% redn. of cloned interleukin 2-dependent cytolytic T lymphocytes.

REFERENCE 2: 113:78901 Preparation of 5'-deoxy-5'-aminoadenosine derivatives as S-adenosylmethionine decarboxylase inhibitors. Casara, Patrick; Danzin, Charles (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 351475 A1 19900124, 20 pp. DESIGNATED STATES: R: FR. (English).

Searched by: Mary Hale 308-4258 CM-1 12D16


GI



AB The title compds. [I; R = NR₁ZNH₂; R₁ = H, Me, Et; Z = CV1V2C(:CXY)CH₂, CV1V2C.tplbond.CCH₂, Q, cis-CV1V2CW:CZ1CH, CV1V2CR2FCH₂, CH₂CH₂CWZ1CH₂; R₂ = H, F; n = 1, 2; V₁ = H, Me; V₂ = H, CO₂H; W, X, Y, Z = H, F, Cl, Br] are prepd. I are potent and irreversible inhibitors of S-adenosylmethionine decarboxylase, and therefore significantly interfere with the formation of spermine and spermidine, and are useful for treatment of diseases assocd. with the rapid proliferation of normal and transformed cells (no data). I in combination with an ornithine decarboxylase (ODC) inhibitor are useful as postcoital contraceptives and menstruation inducers. Antitumor agents in conjunction with I lower side effects and increase survival time. I alone or in combination with an ODC inhibitor may be used as parasiticides, bactericides, fungicides or virucides. Thus, a soln. of cis-Me₃CO₂CNHCH₂CH:CHCH₂Cl, 5'-deoxy-5'-methylamino-2',3'-isopropylideneadenosine, K₂CO₃, and NaI in MeCN was refluxed overnight to give, after hydrolysis with 1N aq. H₂SO₄, I (R = cis-H₂NCH₂CH:CHCH₂NMe). A total of 9 I were prepd.

L31 ANSWER 17 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 128490-17-5 REGISTRY
 CN Adenosine, 5'-deoxy-5'-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-propenyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Furo[3,4-d]-1,3-dioxole, adenosine deriv.
 FS STEREOSEARCH
 MF C23 H35 N7 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 117:70267 Preparation of 5-amino group-containing adenosine analogs as immunosuppressants.. Bowlin, Terry L. (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 472181 A2 19920226, 28 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1991-113994 19910821. PRIORITY: US 1990-571042 19900822.

GI




I

AB The title compds. [I; R = H, Me, Et; Q = (substituted) amino-2-butenyl, (substituted) aminopropyl, (substituted) butynyl, (substituted) aminofluoropropyl, (substituted) aminobutyl, etc.; cis-N-tert-Butoxycarbonyl-4-chloro-2-butenylamine (prepn. given) was refluxed with 5'-deoxy-5'-(methylamino)-2',3'-isopropylideneadenosine in MeCN contg. K₂CO₃ and NaI overnight to give, after deprotection (H₂SO₄ at room temp. for 2 days), cis-5'-deoxy-5'-(4-amino-2-butenyl)methylaminoadenosine. This at 100 .mu.M showed 64% redn. of cloned interleukin 2-dependent cytolytic T lymphocytes.

REFERENCE 2: 113:78901 Preparation of 5'-deoxy-5'-aminoadenosine derivatives as S-adenosylmethionine decarboxylase inhibitors. Casara, Patrick; Danzin, Charles (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 351475 A1 19900124, 20 pp. DESIGNATED STATES: R: FR. (English).

Searched by: Mary Hale 308-4258 CM-1 12D16

GI



AB The title compds. [I; R = NR₁NH₂; R₁ = H, Me, Et; Z = CV1V2C(:CXY)CH₂, CV1V2C.tplbond.CCH₂, Q, cis-CV1V2CW:CZ1CH, CV1V2CR2FCH₂, CH₂CH₂CWZ1CH₂; R₂ = H, F; n = 1, 2; V1 = H, Me; V2 = H, CO₂H; W, X, Y, Z = H, F, Cl, Br] are prepd. I are potent and irreversible inhibitors of S-adenosylmethionine decarboxylase, and therefore significantly interfere with the formation of spermine and spermidine, and are useful for treatment of diseases assocd. with the rapid proliferation of normal and transformed cells (no data). I in combination with an ornithine decarboxylase (ODC) inhibitor are useful as postcoital contraceptives and menstruation inducers. Antitumor agents in conjunction with I lower side effects and increase survival time. I alone or in combination with an ODC inhibitor may be used as parasiticides, bactericides, fungicides or virucides. Thus, a soln. of cis-Me₃CO₂CNHCH₂CH:CHCH₂Cl, 5'-deoxy-5'-methylamino-2',3'-isopropylideneadenosine, K₂CO₃, and NaI in MeCN was refluxed overnight to give, after hydrolysis with 1N aq. H₂SO₄, I (R = cis-H₂NCH₂CH:CHCH₂NMe). A total of 9 I were prepd.

L31 ANSWER 18 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 124464-13-7 REGISTRY

CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-1,5-dideoxy-6-C-[[1-[(1-methylethoxy)carbonyl]oxy]ethoxy]carbonyl]-, 1-[[[(1-methylethoxy)carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Furo[3,2-b]furan, .alpha.-L-talo-oct-4-enofuranuronic acid deriv.

MF C26 H33 N5 O14

SR CA

LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1967 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:36385 Preparation of griseolic acid diester derivatives for treatment of glaucoma. Kaneko, Masakatsu; Kimura, Misako; Kamokari, Makoto; Yokoyama, Tomihisa; Yamazaki, Mitsuo (Sankyo Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 01146895 A2 19890608 Heisei, 15 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1987-306199 19871202.

GI



AB The title compds. [I; R1, R2 = H, (un)protected OH; R3, R4 = H or R3R4 = bond; R5, R6 = R7CO2CHR8, R9CO2CHR10, Q; R7, R8 = straight chain or branched C1-10 alkyl, C3-10 cycloalkyl; R8, R10 = H, straight chain or branched C1-10 alkyl, C3-10 cycloalkyl; R11 = straight chain or branched C1-10 alkyl, C3-10 cycloalkyl, C6-10 aryl] and its salts which show good activity for lowering the intraocular pressure of eye and are useful for treatment of glaucoma, are prepd. Thus, MeCN was added to griseolic acid followed by 1,8-diazabicyclo[5.4.0]-7-undecene with stirring under N. To the resulting mixt., Me3CCO2CH2I was added under ice-cooling and the mixt. was stirred 1 h at room temp. to give 60.5% griseolic acid 8',9'-dipivaloyloxymethyl ester (II). II 0.002% soln. (50 .mu.L) in 0.4% NaCl was applied twice to a rabbit's eye, the intraocular pressure was lowered by a factor of 0.77 over that of the eye treated with 0.5% timolol. An ophthalmic soln. (100 mh, pH 7.0) contg. II 0.002, Na2HPO4 0.716, NaH2PO4 0.728, NaCl 0.400, p-HOC6H4CO2Me 0.026, p-HOC6H4CO2Pr 0.014 g, q.s. H2O, and q.s. NaOH.

L31 ANSWER 19 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 124254-63-3 REGISTRY

CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-6-C-carboxy-1,5-dideoxy-, 8-[1-[(1-methylethoxy)carbonyl]oxy]ethyl ester, 7-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN Furo[3,2-b]furan, .alpha.-L-talo-oct-4-enofuranuronic acid deriv.

MF C25 H31 N5 O12

SR CA

LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:21258 Griseolic acid monesters, their preparation and use in treatment of ophthalmic disorders. Kaneko, Masakatsu; Kimura, Misako; Kamokari, Makoto; Yokoyama, Tomihisa; Yamazaki, Mitsuo; Hirai, Koichi; Sato, Susumu; Yasumoto, Takashi (Sankyo Co., Ltd., Japan). Eur. Pat. Appl. EP 319316 A2 19890607, 112 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1988-311441 19881202. PRIORITY: JP 1987-306200 19871202; JP 1988-162882 19880630.


GI



AB The title compds. [I; R1, R2 = H, (un)protected HO; R3, R4 = H or R3R4 = bond; one of R5, R6 = H, and the other = a carboxy-protecting group removable in the biochem. environment of the human eye], useful for the treatment of ophthalmic disorders, were prepd. To a soln. of 5 g griseolic acid in Me2SO was added 2.7 mL 1,8-diazabicyclo[5.4.0]-7-undecene under N followed successively by MeCN and 3.83 g iodomethyl pivalate with ice-cooling and then the mixt. was allowed to react at room temp. for 5 h to give, after aq. processing and purifn. by chromatog., 10.6% 9'-pivaloyloxymethyl griseolate (II). Instillation of II (50 .mu.L of 1% w/v soln.) into the anesthetized left or right eye of rabbits reduced the intraocular pressure by 2.38 mmHg over the other untreated eye vs. 1.0 mmHg for timolol. An ophthalmic soln. contg. II 1.0, disodium phosphate 0.716, monosodium phosphate 0.728, NaCl 0.400, Me p-hydroxybenzoate 0.026, Pr p-hydroxybenzoate 0.014 g, sterile purified H2O q.s., and NaOH q.c. was prepd.

Searched by: Mary Hale 308-4258 CM-1 12D16

L31 ANSWER 20 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 124254-40-6 REGISTRY
 CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-6-C-carboxy-1,5-dideoxy-, 8-[1-[(1-methylethoxy)carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Furo[3,2-b]furan, .alpha.-L-talo-oct-4-enofuranuronic acid deriv.
 MF C20 H23 N5 O11
 SR CA
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:21258 Griseolic acid monesters, their preparation and use in treatment of ophthalmic disorders. Kaneko, Masakatsu; Kimura, Misako; Kamokari, Makoto; Yokoyama, Tomihisa; Yamazaki, Mitsuo; Hirai, Koichi; Sato, Susumu; Yasumoto, Takashi (Sankyo Co., Ltd., Japan). Eur. Pat. Appl. EP 319316 A2 19890607, 112 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1988-311441 19881202. PRIORITY: JP 1987-306200 19871202; JP 1988-162882 19880630.

GI




AB The title compds. [I; R1, R2 = H, (un)protected HO; R3, R4 = H or R3R4 = bond; one of R5, R6 = H, and the other = a carboxy-protecting group removable in the biochem. environment of the human eye], useful for the treatment of ophthalmic disorders, were prepd. To a soln. of 5 g griseolic acid in Me2SO was added 2.7 mL 1,8-diazabicyclo[5.4.0]-7-

Searched by: Mary Hale 308-4258 CM-1 12D16

undecene under N followed successively by MeCN and 3.83 g iodomethyl pivalate with ice-cooling and then the mixt. was allowed to react at room temp. for 5 h to give, after aq. processing and purifn. by chromatog., 10.6% 9'-pivaloyloxymethyl griseolate (II). Instillation of II (50 .mu.L of 1% w/v soln.) into the anesthetized left or right eye of rabbits reduced the intraocular pressure by 2.38 mmHg over the other untreated eye vs. 1.0 mmHg for timolol. An ophthalmic soln. contg. II 1.0, disodium phosphate 0.716, monosodium phosphate 0.728, NaCl 0.400, Me p-hydroxybenzoate 0.026, Pr p-hydroxybenzoate 0.014 g, sterile purified H2O q.s., and NaOH q.c. was prepd.

L31 ANSWER 21 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 121032-16-4 REGISTRY
 CN Adenosine, 5'-[[3-[1,2-bis[(1,1-dimethylethoxy)carbonyl]hydrazino]propyl]methylamino]-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Furo[3,4-d]-1,3-dioxole, adenosine deriv..
 FS STEREOSEARCH
 MF C27 H44 N8 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 111:23916 Preparation of 5-deoxy-5-O-substituted adenosine derivatives as inhibitors of S-adenosylmethionine decarboxylase. Secrist, John A., III (Southern Research Institute, USA). U.S. US 4794174 A 19881227, 10 pp. (English). CODEN: USXXAM. APPLICATION: US 1987-13061 19870210.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16



AB The title adenosine derivs. [I; X = NH, NMe, S, MeS+; n = 2-4; Z = NHC(:NH)NH₂, NHC(:NH)NHNH₂, NHCONHNH₂, NHNH₂, NHCON(NO)Me, NHC(S)NHNH₂] were prepd. as S-adenosylmethionine decarboxylase (AdoMet-DC) inhibitors. Reaction of 2',3'-O-isopropylidene-5'-O-tosyladenosine with MeNH(CH₂)₃OH in DMF for 40 h gave 72% 5'-deoxy-2',3'-O-isopropylidene-5'-[N-methyl-N-(3-hydroxypropyl)]amino adenosine which was treated with Me₃CO₂CN:NCO₂CMe₃ and Ph₃P in THF to give 75% 5'-deoxy-2',3'-isopropylidene-5'-[N-methyl-N-[3-[1,2-bis(1,1-dimethylethoxy)carbonyl]hydrazino]propyl]]aminoadenosine. Hydrolysis of the latter in a 1:1 mixt. of dioxane and 1 M H₂SO₄ at 70.degree. for 2 h gave 65% I (Z = NHNH₂, n = 3, X = NMe) (II). II inhibited AdoMet-DC with an ID₅₀ of 0.08 .mu.M.

L31 ANSWER 22 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 119898-90-7 REGISTRY

CN Carbamic acid, [2-[[2-[1-(6-amino-9H-purin-9-yl)-2-hydroxyethoxy]-3-hydroxypropyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [1S-[1R*,2[R*(S*)]]]- (9CI) (CA INDEX NAME)

MF C27 H31 N7 O6

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 110:154786 The chemistry of 2',3'-seconucleosides. III.
Synthesis and reactions of purine-2',3'-secoribonucleosides. Beaton,

Searched by: Mary Hale 308-4258 CM-1 12D16

Graham; Jones, A. Stanley; Walker, Richard T. (Chem. Dep., Univ. Birmingham, Birmingham, B15 2TT, UK). Tetrahedron, 44(20), 6419-28 (English) 1988. CODEN: TETRAB. ISSN: 0040-4020.

AB 5'-O-Protected purine-ribonucleosides were oxidized with periodate to give dialdehydes which upon redn. with sodium borohydride gave 5'-O-protected purine-2',3'-secoribonucleosides, which were converted into their 2',3'-di-O-mesyl derivs.. These were converted into 2',3'-disubstituted-2',3'-dideoxy derivs. and because the 2'-O-mesyl group was significantly less reactive than the 3'-O-mesyl group, selective substitution at either the 2' or 3'-positions was achieved. As an example of the latter procedure, syntheses of 3'-amino-3'-deoxy-2',3'-secoadenosine and of 3'-deoxy-2',3'-secoinosine are described. The former compd. was used as the starting material for the synthesis of a secopuromycin analog.

L31 ANSWER 23 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 119830-85-2 REGISTRY
CN Carbamic acid, [2-[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 N7 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.


GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prepd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

Searched by: Mary Hale 308-4258 CM-1 12D16

L31 ANSWER 24 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 119830-84-1 REGISTRY
 CN Carbamic acid, [2-[[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C22 H21 N7 O3
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
 (*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.


GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prep'd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 25 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 119805-77-5 REGISTRY
 CN Carbamic acid, [1-[[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H29 N7 O3
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prepd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 26 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 119805-68-4 REGISTRY
CN Carbamic acid, [1-[[[4-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C28 H33 N7 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)




Searched by: Mary Hale 308-4258 CM-1 12D16

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R₁ = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prepd. from the nitrobenzylpurines. Only I (R = Me, R₁ = m-H-Phe-NH) and the intermediate I (R = Me, R₁ = m - NH₂) had activity against rhinovirus 1B.

L31 ANSWER 27 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 119805-67-3 REGISTRY
CN Carbamic acid, [2-[[2-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N7 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res.

Searched by: Mary Hale 308-4258 CM-1 12D16

Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prepd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 28 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 119805-61-7 REGISTRY


CN Carbamic acid, [1-[[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

MF C26 H29 N7 O3 . Cl H

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)

CRN (119805-77-5)




● HCl

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prep'd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 29 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 119805-60-6 REGISTRY
 CN Carbamic acid, [1-[[[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H29 N7 O3
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
 (*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prep'd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 30 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 119805-55-9 REGISTRY

CN Carbamic acid, [2-[[4-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C24 H25 N7 O3

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT

(*File contains numerically searchable property data)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:154822 Synthesis and antiviral activity of 6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234.

GI



AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prep'd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

L31 ANSWER 31 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 108257-20-1 REGISTRY

CN Adenosine, 5'-deoxy-5'-[[1-oxo-4-[[(phenylmethoxy)carbonyl]amino]butyl]amino]- (9CI) (CA INDEX NAME)

Searched by: Mary Hale 308-4258 CM-1 12D16

FS STEREOSEARCH
 MF C22 H27 N7 O6
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER
 (*File contains numerically searchable property data)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 106:214262 Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation. Lever, O. William, Jr.; Vestal, B. Randall (Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA). J. Heterocycl. Chem., 23(3), 901-3 (English) 1986. CODEN: JHTCAD. ISSN: 0022-152X.

GI




AB Twelve title compds. I (R = NO, NO₂; n = 2, 3, 4, 5, 6, 7) were prepd. from the corresponding H₂N(CH₂)_nCO₂H by sequential N-benzyloxycarbonylation with PhCH₂OCOC₂H₅, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzyloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitroisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.

L31 ANSWER 32 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 108257-19-8 REGISTRY
 CN Adenosine, 5'-deoxy-5'-[[1-oxo-3-[[(phenylmethoxy) carbonyl] amino] propyl] am

Searched by: Mary Hale 308-4258 CM-1 12D16

ino]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H25 N7 O6
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER
 (*File contains numerically searchable property data)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 106:214262 Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation. Lever, O. William, Jr.; Vestal, B. Randall (Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA). J. Heterocycl. Chem., 23(3), 901-3 (English) 1986. CODEN: JHTCAD. ISSN: 0022-152X.

GI




AB Twelve title compds. I (R = NO, NO₂; n = 2, 3, 4, 5, 6, 7) were prepd. from the corresponding H₂N(CH₂)_nCO₂H by sequential N-benzyloxycarbonylation with PhCH₂OCOC₂H₅, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzyloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitrosoisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.

L31 ANSWER 33 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 103618-96-8 REGISTRY

Searched by: Mary Hale 308-4258 CM-1 12D16

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
 [[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-,
 ethyl ester, (R)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H31 N7 O7 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79329 Structure activity relationships of synthetic
 antibiotic analogs of chryscandin. Komori, Tadaaki; Sakane, Kazuo; Setoi,
 Hiroyuki; Kawai, Yoshio; Teraji, Tsutomu; Kohsaka, Masanobu; Imanaka,
 Hiroshi (Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan).
 J. Antibiot., 38(9), 1182-203 (English) 1985. CODEN: JANTAJ. ISSN:
 0021-8820.

GI



Searched by: Mary Hale 308-4258 CM-1 12D16

AB Chryscondin (I) and 98 analogs, e.g. II (R = OH, NHNH₂, etc.; R₁ = H-Phe, H-Cys, etc.), were prepd. and their antibacterial activities were detd. Thus, Z-Tyr(Me)-OH (Z = PhCH₂O₂C) was condensed with amino nucleoside III (R₂ = H) by DCC/N-hydroxysuccinimide to give III [R₂ = Z-Tyr(Me)], which was deblocked by BuNH₂ and hydrogenolysis to give I. II (R = OH, R₁ = H-Cys) showed the highest efficacy against *Candida albicans*.

L31 ANSWER 34 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 103618-94-6 REGISTRY

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]-, (R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C24 H29 N7 O7 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79329 Structure activity relationships of synthetic antibiotic analogs of chryscondin. Komori, Tadaaki; Sakane, Kazuo; Setoi, Hiroyuki; Kawai, Yoshio; Teraji, Tsutomu; Kohsaka, Masanobu; Imanaka, Hiroshi (Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan). J. Antibiot., 38(9), 1182-203 (English) 1985. CODEN: JANTAJ. ISSN: 0021-8820.

GI



AB Chryscandin (I) and 98 analogs, e.g. II (R = OH, NHNH₂, etc.; R₁ = H-Phe, H-Cys, etc.), were prepd. and their antibacterial activities were detd. Thus, Z-Tyr(Me)-OH (Z = PhCH₂O₂C) was condensed with amino nucleoside III (R₂ = H) by DCC/N-hydroxysuccinimide to give III [R₂ = Z-Tyr(Me)], which was deblocked by BuNH₂ and hydrogenolysis to give I. II (R = OH, R₁ = H-Cys) showed the highest efficacy against *Candida albicans*.

L31 ANSWER 35 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 103618-93-5 REGISTRY

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C24 H29 N7 O7 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79329 Structure activity relationships of synthetic antibiotic analogs of chryscandin. Komori, Tadaaki; Sakane, Kazuo; Setoi, Hiroyuki; Kawai, Yoshio; Teraji, Tsutomu; Kohsaka, Masanobu; Imanaka, Hiroshi (Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan). J. Antibiot., 38(9), 1182-203 (English) 1985. CODEN: JANTAJ. ISSN: 0021-8820.

GI



AB Chryscandin (I) and 98 analogs, e.g. II (R = OH, NHNH₂, etc.; R1 = H-Phe, H-Cys, etc.), were prepd. and their antibacterial activities were detd. Thus, Z-Tyr(Me)-OH (Z = PhCH₂O₂C) was condensed with amino nucleoside III (R2 = H) by DCC/N-hydroxysuccinimide to give III [R2 = Z-Tyr(Me)], which was deblocked by BuNH₂ and hydrogenolysis to give I. II (R = OH, R1 = H-Cys) showed the highest efficacy against Candida albicans.

L31 ANSWER 36 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 103618-92-4 REGISTRY

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C27 H35 N7 O7 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79329 Structure activity relationships of synthetic antibiotic analogs of chryscandin. Komori, Tadaaki; Sakane, Kazuo; Setoi, Hiroyuki; Kawai, Yoshio; Teraji, Tsutomu; Kohsaka, Masanobu; Imanaka, Hiroshi (Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan). J. Antibiot., 38(9), 1182-203 (English) 1985. CODEN: JANTAJ. ISSN: 0021-8820.

GI




AB Chryscandin (I) and 98 analogs, e.g. II (R = OH, NHNH₂, etc.; R₁ = H-Phe, H-Cys, etc.), were prepd. and their antibacterial activities were detd. Thus, Z-Tyr(Me)-OH (Z = PhCH₂O₂C) was condensed with amino nucleoside III (R₂ = H) by DCC/N-hydroxysuccinimide to give III [R₂ = Z-Tyr(Me)], which was deblocked by BuNH₂ and hydrogenolysis to give I. II (R = OH, R₁ = H-Cys) showed the highest efficacy against *Candida albicans*.

L31 ANSWER 37 OF 119 REGISTRY COPYRIGHT 2002 ACS

Searched by: Mary Hale 308-4258 CM-1 12D16

RN 103582-77-0 REGISTRY
 CN L-Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-.gamma.-glutamyl]-L-phenylalanyl]-, 1-methyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H36 N8 O8
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79332 Synthesis of nucleic acid analogs of natural nucleopeptides. Ryabtseva, O. N.; Semiletov, Yu. A.; Korshunova, G. A.; Shvachkin, Yu. P. (Mosk. Gos. Univ., Moscow, USSR). Zh. Obshch. Khim., 55(11), 2633-4 (Russian) 1985. CODEN: ZOKHA4. ISSN: 0044-460X.
 AB Fifteen analogs of H-.gamma.-Glu-X-Ual-OH [I; Ual = L-.beta.-(uracilyl-N1)-.alpha.-alanine residue; X = null or Phe], in which Ual is replaced by .beta.-(thyminy-N1)-.alpha.-alanine or .beta.-(adeniny-N9)-.alpha.-alanine, were prepd. by the soln. method using pentafluorophenyl esters for peptide couplings. I have been previously isolated from seeds of Fagus silvatica.

L31 ANSWER 38 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 103582-76-9 REGISTRY
 CN L-Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-.gamma.-glutamyl]-L-phenylalanyl]-, 1-methyl 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C35 H42 N8 O8
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:79332 Synthesis of nucleic acid analogs of natural nucleopeptides. Ryabtseva, O. N.; Semiletov, Yu. A.; Korshunova, G. A.; Shvachkin, Yu. P. (Mosk. Gos. Univ., Moscow, USSR). Zh. Obshch. Khim., 55(11), 2633-4 (Russian) 1985. CODEN: ZOKHA4. ISSN: 0044-460X.

AB Fifteen analogs of H-.gamma.-Glu-X-Ual-OH [I; Ual = L-.beta.-(uracilyl-N1)-.alpha.-alanine residue; X = null or Phe], in which Ual is replaced by .beta.-(thyminy-N1)-.alpha.-alanine or .beta.-(adeniny-N9)-.alpha.-alanine, were prepd. by the soln. method using pentafluorophenyl esters for peptide couplings. I have been previously isolated from seeds of Fagus silvatica.

L31 ANSWER 39 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93097-09-7 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenyldithio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C26 H33 N7 O7 S2

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

Searched by: Mary Hale 308-4258 CM-1 12D16


GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 40 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93097-08-6 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[{(1,1-dimethylethoxy)carbonyl]amino]-3-[[[1-[(1,1-dimethylethoxy)carbonyl]-5-methyl-1H-imidazol-4-yl]methyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C30 H43 N9 O9 S
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 41 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93097-07-5 REGISTRY

CN Pentofuranuronic acid, 3-[[[3-[[[5-(acetylamino)-1,2,4-thiadiazol-3-yl]methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:



CN 1,2,4-Thiadiazole, pentofuranuronic acid deriv.

FS 3D CONCORD

MF C25 H34 N10 O8 S2

LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 42 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93097-06-4 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(tetrahydro-2H-pyran-2-yl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H37 N7 O8 S

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16



REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 43 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93097-05-3 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(3-pyridinylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H34 N8 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.


GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 44 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93097-04-2 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(2-pyridinylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H34 N8 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A



PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Searched by: Mary Hale 308-4258 CM-1 12D16

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 45 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93097-03-1 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-pyridinylthio)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H30 N8 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan): Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 46 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93097-02-0 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-


Searched by: Mary Hale 308-4258 CM-1 12D16

dimethylethoxy)carbonyl]amino]-3-[(2-furanylmethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H33 N7 O8 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL

Searched by: Mary Hale 308-4258 CM-1 12D16

H₂O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me₃CO₂, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH₂, R₁ = Boc-Cys(Me)-NH, R₂ = CO₂Et, R₃ = H]. I [R, R₁, R₂, R₃ = NH₂, Met-NH, CO₂H, H; NH₂, H-Cys(CH₂CH:CH₂)-NH, CO₂H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 47 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93097-01-9 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(2-thienylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H33 N7 O7 S2
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 48 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93097-00-8 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C27 H42 N8 O9 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 49 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93096-99-2 REGISTRY


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[[(2-chlorophenyl)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C27 H34 Cl N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP.
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 50 OF 119 REGISTRY COPYRIGHT 2002 ACS



RN 93096-98-1 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[[4-chlorophenyl)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C27 H34 Cl N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.


GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 51 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-97-0 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[(4-methylphenyl)methyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H37 N7 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 52 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-96-9 REGISTRY
CN Pentofuranuronic acid, 3-[[3-[[[acetylamino)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H34 N8 O8 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 53 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-95-8 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(3-phenyl-2-propenyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C29 H37 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 54 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-94-7 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-propynylthio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H31 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 55 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-93-6 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-propenylthio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H33 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 56 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-92-5 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(1,1-dimethylethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H37 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 57 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-91-4 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H35 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R =
(substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3
= H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus,
stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL
H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL
THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2
= CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2,
H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2
.mu.g/mL, resp.

L31 ANSWER 58 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-90-3 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-
dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]- (9CI)
(CA INDEX NAME)

FS 3D CONCORD

MF C24 H29 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 59 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-89-0 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-(methylthio)-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H33 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 60 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-88-9 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H29 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R =
(substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3
= H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus,
stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL
H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL
THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2
= CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2,
H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2
.mu.g/mL, resp.

L31 ANSWER 61 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-87-8 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-
dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-, ethyl
ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H31 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)



REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 62 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-71-0 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[(4-methoxyphenyl)methyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H37 N7 O8 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1967 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 63 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-69-6 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(1-phenylethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H37 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 64 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-59-4 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-(methylthio)-1-oxopentyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H35 N7 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 65 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-58-3 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-4-(2-propenylthio)butyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H35 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 66 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-56-1 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(2-ethoxy-2-oxoethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H35 N7 O9 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.


GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 67 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-55-0 REGISTRY
 CN Pentofuranuronic acid, 3-[[3-[[[4-(acetyloxy)phenyl]methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C29 H37 N7 O9 S
 LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 68 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-54-9 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-[(2,3-dichloro-2-propenyl)thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H31 Cl2 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 69 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-53-8 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-[(1-methylethyl)thio]-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H37 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 70 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-52-7 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-cyclohexen-1-ylthio)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H37 N7 O7 S
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)


1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.

(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.

APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.


L31 ANSWER 71 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93096-51-6 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-

Searched by: Mary Hale 308-4258 CM-1 12D16

dimethylethoxy)carbonyl]amino]-4-(ethylthio)-1-oxobutyl]amino]-, ethyl
 ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C23 H35 N7 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)



REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R =
 (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3
 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus,
 stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL
 H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL
 THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2
 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2,
 H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2
 .mu.g/mL, resp.

L31 ANSWER 72 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-50-5 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-[[[4-
 (dimethylamino)phenyl]methyl]thio]-2-[[[1,1-dimethylethoxy)carbonyl]amino]-
 1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C29 H40 N8 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 73 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-32-3 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methyldithio)-1-oxopropyl]amino]- (9CI)
 (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H27 N7 O7 S2
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 74 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93096-31-2 REGISTRY


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[[(2-amino-4-thiazolyl)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C24 H33 N9 O7 S2

LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 75 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93096-30-1 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(4-pyridinyl)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H30 N8 O7
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.


L31 ANSWER 76 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 93096-29-8 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[[3-(5-amino-1,2,4-thiadiazol-3-yl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-

Searched by: Mary Hale 308-4258 CM-1 12D16

oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2,4-Thiadiazole, pentofuranuronic acid deriv.
 FS 3D CONCORD
 MF C21 H28 N10 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R =
 (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3
 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus,
 stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL

Searched by: Mary Hale 308-4258 CM-1 12D16

H₂O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me₃CO₂, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH₂, R₁ = Boc-Cys(Me)-NH, R₂ = CO₂Et, R₃ = H]. I [R, R₁, R₂, R₃ = NH₂, Met-NH, CO₂H, H; NH₂, H-Cys(CH₂CH:CH₂)-NH, CO₂H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 77 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-28-7 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-amino-4-pyrimidinyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H32 N10 O7
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 78 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-27-6 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-thienyl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H31 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 79 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-26-5 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(1H-pyrrol-2-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H32 N8 O7

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)


1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;

Searched by: Mary Hale 308-4258 CM-1 12D16

GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 80 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-24-3 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-2-O-methyl-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C22 H33 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.


(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP

59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.

APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;


GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 81 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-13-0 REGISTRY
 CN Ethanesulfonic acid, 2-[[[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pentofuranuronoyl]amino]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C27 H36 N8 O9 S2
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 82 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-12-9 REGISTRY
 CN Glycine, N-[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pentofuranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C28 H36 N8 O8 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 83 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-11-8 REGISTRY
 CN Phosphonic acid, [2-[[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pentofuranuronoyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C31 H45 N8 O9 P S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 84 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93096-10-7 REGISTRY
 CN Pentofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-N-hydroxy- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C25 H32 N8 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 85 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93096-08-3 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H31 N7 O7 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 86 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93095-97-7 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[2-[(trifluoroacetyl)amino]-5-thiazolyl]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H30 F3 N9 O8 S

LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 87 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93095-94-4 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[1-[(1,1-dimethylethoxy)carbonyl]-1H-imidazol-4-yl]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C26 H35 N9 O9

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 88 OF 119 REGISTRY COPYRIGHT 2002 ACS

Searched by: Mary Hale 308-4258 CM-1 12D16

RN 93095-93-3 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[[3-[(1,1-dimethylethoxy)carbonyl]-4-thiazolidinyl]carbonyl]amino]-, ethyl ester
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H29 N7 O7 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 89 OF 119 REGISTRY COPYRIGHT 2002 ACS

Searched by: Mary Hale 308-4258 CM-1 12D16

RN 93095-92-2 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(3-pyridinyl)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C24 H30 N8 O7
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2,

Searched by: Mary Hale 308-4258 CM-1 12D16

H-Cys(CH₂CH:CH₂)-NH, CO₂H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 90 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93095-91-1 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenyldithio)propyl]amino]- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C24 H29 N7 O7 S2
LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI




AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH₂). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH₂, R2 = CO₂Et, R3 = H), 75 mL H₂O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me₃CO₂, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH₂, R1 = Boc-Cys(Me)-NH, R2 = CO₂Et, R3 = H]. I [R, R1, R2, R3 = NH₂, Met-NH, CO₂H, H; NH₂, H-Cys(CH₂CH:CH₂)-NH, CO₂H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 91 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 93095-86-4 REGISTRY
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfonyl)-1-oxopropyl]amino]-,

Searched by: Mary Hale 308-4258 CM-1 12D16

ethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C21 H31 N7 O9 S
 LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
 (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
 GB 1983-3473 19830208.


GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 92 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 93095-85-3 REGISTRY
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfonyl)-1-oxopropyl]amino]-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C19 H27 N7 O9 S
 LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 93 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93095-82-0 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfinyl)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C21 H31 N7 O8 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofurancarboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 94 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 93095-81-9 REGISTRY

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-(methylsulfinyl)-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C22 H33 N7 O8 S

LC STN Files: CA, CAPLUS, TOXCENTER




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 101:231024 Tetrahydrofuran carboxylic acid derivatives.
(Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP
59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF.
APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105;
GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prep'd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.

L31 ANSWER 95 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 86937-99-7 REGISTRY


CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-methoxyphenyl)-1-oxopropyl]amino]-, (S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C25 H31 N7 O8

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.


GI



AB Title compds. I ($R = \text{NH}_2$ or protected NH_2 ; $R_1 = \text{NH}_2$ or acylamino; $R_2 = \text{CO}_2\text{H}$ or protected CO_2H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degra. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III ($R_3 = \text{Bz}$, $R_4 = \text{azido}$) (IV) over Pd/C to give III ($R_3 = \text{Bz}$, $R_4 = \text{NH}_2$), which was coupled with Z-Tyr(Me)-OH ($Z = \text{PhCH}_2\text{O}_2\text{C}$) by DCC/N-hydroxysuccinimide (HONSu) to give III [$R_3 = \text{Bz}$, $R_4 = \text{Z-Tyr(Me)-NH}$], which was debenzoylated by refluxing in MeOH/ BuNH_2 and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III ($R_3 = \text{Bz}$, $R_4 = \text{Z-Phe-NH}$), which was debenzoylated and then Z-deblocked to give III ($R_3 = \text{H}$, $R_4 = \text{H-Phe-NH}$) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 96 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-95-3 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
 [[(1,1-dimethylethoxy)carbonyl]amino]-1,5-dioxo-5-
 (phenylmethoxy)pentyl]amino]-, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H33 N7 O9
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.


GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degridn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 97 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-85-1 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-(2-methoxy-2-oxoethoxy)phenyl]-1-oxopropyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H35 N7 O10
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI




Searched by: Mary Hale 308-4258 CM-1 12D16

AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 98 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-83-9 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]phenyl]-1-oxopropyl]amino]-, ethyl ester, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C34 H48 N8 O10
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A






— OBU-t

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.


GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prep'd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was det'd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prep'd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prep'd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 99 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-81-7 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenyl)-1-oxopropyl]amino]-ethyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H32 N8 O9
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofuran carboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

Searched by: Mary Hale 308-4258 CM-1 12D16

GI




AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂CO₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 100 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-78-2 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H42 N8 O9
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI



II



III

AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 101 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 86937-75-9 REGISTRY


CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-chlorophenyl)-2-[[[1,1-dimethylethoxy]carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H32 Cl N7 O7

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prep'd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was det'd. by an anal. of its phys. and chem. properties and by chem. degridn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prep'd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prep'd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 102 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 86937-73-7 REGISTRY

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[[3-(3-chlorophenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C25 H30 Cl N7 O7

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)


1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI



II




III

AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prep'd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prep'd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prep'd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 103 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-71-5 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[[3-(4-chlorophenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H30 Cl N7 O7
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

Searched by: Mary Hale 308-4258 CM-1 12D16

GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 104 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 86937-40-8 REGISTRY

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[1-oxo-3-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C21 H23 N7 O7

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI



II




III

AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 105 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-39-5 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-1-[[1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]-, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H23 N7 O7
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL,

Searched by: Mary Hale 308-4258 CM-1 12D16

SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731.
 PRIORITY: GB 1981-24352 19810810.

GI




AB Title compds. I ($R = \text{NH}_2$ or protected NH_2 ; $R_1 = \text{NH}_2$ or acylamino; $R_2 = \text{CO}_2\text{H}$ or protected CO_2H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III ($R_3 = \text{Bz}$, $R_4 = \text{azido}$) (IV) over Pd/C to give III ($R_3 = \text{Bz}$, $R_4 = \text{NH}_2$), which was coupled with Z-Tyr(Me)-OH ($Z = \text{PhCH}_2\text{O}_2\text{C}$) by DCC/N-hydroxysuccinimide (HONSu) to give III [$R_3 = \text{Bz}$, $R_4 = \text{Z-Tyr(Me)-NH}$], which was debenzoylated by refluxing in MeOH/ BuNH_2 and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III ($R_3 = \text{Bz}$, $R_4 = \text{Z-Phe-NH}$), which was debenzoylated and then Z-deblocked to give III ($R_3 = \text{H}$, $R_4 = \text{H-Phe-NH}$) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 106 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-36-2 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
 [[(1,1-dimethylethoxy)carbonyl]amino]-3-methoxy-1-oxo-3-
 phenylpropyl]amino]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H31 N7 O8
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.


GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 107 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-35-1 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
 [[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)-1-
 oxopropyl]amino]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H28 F N7 O7
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofurancarboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.


GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 108 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-34-0 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[[(1,1-dimethylethoxy)carbonyl]amino]phenylacetyl]amino]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H27 N7 O7
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofuran carboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI



II




III

AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene-.alpha.-D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 109 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 86937-32-8 REGISTRY
 CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-
 [[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H29 N7 O7
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 99:122910 Tetrahydrofuran carboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16




AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prep'd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prep'd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prep'd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.

L31 ANSWER 110 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 80361-99-5 REGISTRY
 CN Adenosine, 5'-chloro-3',5'-dideoxy-3'-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-methoxyphenyl)-1-oxopropyl]amino]-N,N-dimethyl-, (S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H36 Cl N7 O6
 LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
 (*File contains numerically searchable property data)

Absolute stereochemistry.

Searched by: Mary Hale 308-4258 CM-1 12D16




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 96:45905 5'-Chloropuromycin. Inhibition of protein synthesis and antitrypanosomal activity. Vince, Robert; Lee, Heejoo; Narang, A. S.; Shiota, Frances N. (Coll. Pharm., Univ. Minnesota, Minneapolis, MN, 55455, USA). J. Med. Chem., 24(12), 1511-14 (English) 1981. CODEN: JMCMAR. ISSN: 0022-2623.

GI



AB I [80362-00-1] and II [43157-40-0], puromycin derivs., were synthesized and tested for their ability to inhibit protein formation in vitro and for their antitrypanosomal activity in mice. Both I and II inhibited protein formation by acting as substrates at the peptidyltransferase site of ribosomes, whereas only I exhibited significant antitrypanosomal activity in mice. In rats, the aminonucleosides released by the in vivo hydrolysis of I and II exhibited no nephrotoxicity, whereas the corresponding aminoglycoside of puromycin caused severe nephrotoxic manifestations.

L31 ANSWER 111 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 75128-66-4 REGISTRY
CN Carbamic acid, [2-[[2-[[6-(dimethylamino)-9H-purin-9-


Searched by: Mary Hale 308-4258 CM-1 12D16

yl]methoxy]propyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester
(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H33 N7 O4

LC STN Files: CA, CAPLUS, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:122620 Purine acyclic nucleosides. 6-Dimethylamino-9-[(2-phenylalanylamido-1-substituted-ethoxy)methyl]purines as candidate antivirals. Kelley, James L.; Selway, J. W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA). J. Pharm. Sci., 74(12), 1302-4 (English) 1985. CODEN: JPMSAE. ISSN: 0022-3549.


GI



AB The title compds., which are puromycin acyclic analogs, and their intermediates (I and II; R¹ = Me, cyclopentyl, or Ph; II; R² = H or PhCH₂CO₂) were prepd., in several steps starting with the phthaloylation of 1-substituted-2-aminoethanols, and test for antiviral activity (adenovirus, herpes simplex 1, vaccinia, influenza virus, etc.) in vitro. The intermediate II (R¹ = cyclopentyl and R² = PhCH₂CO₂) [75128-61-9] was active against 2 of the strains tested.


REFERENCE 2: 93:186414 Compositions for treating viral infections and guanine acyclic nucleosides. Schaeffer, Howard J. (Burroughs Wellcome Co., USA). U.S. US 4199574 19800422, 14 pp. Cont.-in-part of U.S. Ser. No. 608,263, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1976-662900 19760301.

GI



AB Purines I [Z = S, O; R = NH₂; R₁ = OH; R₂ = H, alkyl, hydroxyalkyl; R₃ = H, alkyl, hydroxyalkyl, benzyloxyalkyl, Ph; R₄ = H, OH, alkyl; R₅ = H, OH, NH₂, alkyl, hydroxyalkyl, BzO, benzoyloxyalkyl, PhCH₂O, OSO₂NH₂, OP(O)(OH)₂, carboxypropionyloxy, AcO] were prepd. by different methods; I (R = R₁ = NH₂, Z = O, R₅ = OH, R₂ = R₃ = R₄ = H), which showed antiviral activity, was among the compds. prepd. 6-Chloropurine was alkylated to give 6-chloro-9-(2-benzoyloxyethoxymethyl)purine, and ammonolysis of the product gave 9-(2-hydroxyethoxymethyl)adenine.

L31 ANSWER 112 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 75128-53-9 REGISTRY
 CN Carbamic acid, [2-[[2-[(6-amino-9H-purin-9-yl)methoxy]ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 DR 80613-30-5
 MF C25 H27 N7 O4
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 93:186414 Compositions for treating viral infections and guanine acyclic nucleosides. Schaeffer, Howard J. (Burroughs Wellcome Co., USA). U.S. US 4199574 19800422, 14 pp. Cont.-in-part of U.S. Ser. No. 608,263, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1976-662900 19760301.


GI



AB Purines I [Z = S, O; R = NH₂; R₁ = OH; R₂ = H, alkyl, hydroxyalkyl; R₃ = H, alkyl, hydroxyalkyl, benzyloxyalkyl, Ph; R₄ = H, OH, alkyl; R₅ = H, OH, NH₂, alkyl, hydroxyalkyl, BzO, benzyloxyalkyl, PhCH₂O, OSO₂NH₂, OP(O)(OH)₂, carboxypropionyloxy, AcO] were prepd. by different methods; I (R = R₁ = NH₂, Z = O, R₅ = OH, R₂ = R₃ = R₄ = H), which showed antiviral activity, was among the compds. prepd. 6-Chloropurine was alkylated to give 6-chloro-9-(2-benzyloxyethoxymethyl)purine, and ammonolysis of the product gave 9-(2-hydroxyethoxymethyl)adenine.

L31 ANSWER 113 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 72758-45-3 REGISTRY
CN Benzoic acid, 2-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-.beta.-D-ribofuranuronoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H20 N6 O6
LC STN Files: BEILSTEIN*, CA, CAPLUS, RTECS*
(*File contains numerically searchable property data)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 92:129239 Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides. Prasad, Raj Nandan; Bariana, Dilbagh S.; Fung, Anthony; Savic, Milica; Tietje, Karin; Stein, Herman H.; Brondyk, Harold; Egan, Richard S. (Org. Chem. Res., Abbott Lab., Ltd., Montreal, PQ, H3C 3K6, Can.). J. Med. Chem., 23(3), 313-19 (English) 1980. CODEN: JMCMAR. ISSN: 0022-2623.

GI



AB About 35 adenosinecarboxamides I [R = H, R1 = Me, Et, PhOCH2CH2, Et2NCH2CH2, cyclopropyl, CH2:CHCH2, Ph, adamantyl, etc.; R = R1 = CH2:CHCH2; or (RNR1) = piperidino, morpholino, etc.] and several analogs of I contg. N1-oxide function or 2',3'-substituents were prepd. from II. II was chlorinated with SOCl2, the acid chloride was amidated, and the product was deisopropylidenated to give I. Alternatively II was deisopropylidenated and then converted into the ClCH2CH2 ester, which was amidated to give I. All the compds. prepd. were evaluated for coronary sinus PO2 activity in dogs (extensive data given). 1H-NMR spectra of some of the compds. were examd. and conformations are discussed.

L31 ANSWER 114 OF 119 REGISTRY COPYRIGHT 2002 ACS


RN 58328-53-3 REGISTRY

CN Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[3-(6-amino-9H-purin-9-yl)-N-[(1,1-dimethylethoxy)carbonyl]alanyl]-L-alanyl]-, ethyl ester (9CI) (CA INDEX NAME)

MF C26 H35 N13 O6

LC STN Files: BEILSTEIN*, CA, CAPLUS

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 91:175710 Nucleoamino acids and nucleopeptides. IV. Synthesis

Searched by: Mary Hale 308-4258 CM-1 12D16

of oligonucleopeptides containing uracilyl-N1-.alpha.-alanine and adenylyl-N9-.alpha.-alanine residues. Olsuf'eva, E. N.; Shvachkin, Yu. P. (Mosk. Gos. Univ., Moscow, USSR). Zh. Obshch. Khim., 49(5), 1147-51 (Russian) 1979. CODEN: ZOKHA4. ISSN: 0044-460X.

AB Tripeptides incorporating .beta.-(1-uracilyl)alanine (H-Ual-OH) and .beta.-(9-adenylyl)alanine (H-Aal-OH) were prepd., using activated derivs. of these nucle amino acids. Thus, Boc-Ual-OC6H4NO2-p (Boc = CO2CMe3) reacted with H-Ual-Ala-OMe to give Boc-Ual-Ual-Ala-OMe. Reaction of Boc-Aal-OH with N-hydroxysuccinimide gave the activated ester, which reacted with H-Aal-Ala-OMe or H-Aal-Aal-OEt to give Boc-Aal-Aal-Ala-OMe and Boc-(Aal)3-OEt, resp. The protective groups were removed from these peptides by treatment with 4N HCl in 2:1 dioxane-EtOH.

REFERENCE 2: 84:90565 Homo- and heterotripeptides containing nucleic bases in the side chains. Shvachkin, Yu. P.; Olsuf'eva, E. N. (Mosk. Gos. Univ. im. Lomonosova, Moscow, USSR). Zh. Obshch. Khim., 45(10), 2351-2 (Russian) 1975. CODEN: ZOKHA4.

AB [In this abstr. Ala(3-A) = 3-(6-amino-9H-purin-9-yl)alanine residue, and Ala(3-U) = 3-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)alanine residue]. Me3CO2C-Ala(3-U)-Ala(3-U)-Ala-OMe, Me3CO2C-Ala(3-A)-Ala(3-A)-Ala-OMe, Me3CO2C-Ala(3-A)-Ala(3-U)-Ala(3-A)-OEt, Me3CO2C-Ala(3-A)-Ala-Ala(3-A)-OEt, Me3CO2C-Ala(3-A)-Ala(3-A)-Ala(3-A)-OEt, Ala(3-A)-Ala-Ala(3-A)-OEt.3HCl, and Ala(3-A)-Ala(3-A)-Ala(3-A)-OEt.4HCl were prepd. by std. active ester and dicyclohexylcarbodiimide peptide coupling reactions.

L31 ANSWER 115 OF 119 REGISTRY COPYRIGHT 2002 ACS

RN 52691-29-9 REGISTRY


CN Carbamic acid, [1-[[[3-[6-(dimethylamino)-9H-purin-9-yl]-2-hydroxycyclopentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, [1S-[1.alpha.(R*),2.alpha.,3.beta.]]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H35 N7 O4

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 81:115149 Puromycin analogs. Ribosomal binding with diastereomeric carbocyclic puromycin analogs. Vince, Robert; Daluge, Susan (Coll. Pharm., Univ. Minnesota, Minneapolis, Minn., USA). J. Med. Chem., 17(6), 578-83 (English) 1974. CODEN: JMCMAR.


AB Of 7 title compds. prepd. and found active in the inhibition of poly-UC-directed polyphenylalanine formation in an Escherichia coli cell-free system, 6-(dimethylamino)-9-[(R)-[(2R)-hydroxy-(3R)-(L-phenylalanyl)amino]cyclopentyl]purine (I) [52661-26-4] gave 98.6% inhibition at 10-4M. I was prepd. from 3-acetamidocyclopentene

Searched by: Mary Hale 308-4258 CM-1 12D16

[52661-16-2] by epoxidn., opening of the epoxide with NaN₃ [26628-22-8], followed by redn. to the azido alc., resoln. via tartrate formation, introduction of the purine moiety, and coupling with the amino acid. The relation of structure of the various aminoacyl analogs to activity was discussed.

L31 ANSWER 116 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 52661-25-3 REGISTRY
 CN Carbamic acid, [1-[[[3-[6-(dimethylamino)-9H-purin-9-yl]-2-hydroxycyclopentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, [1R-[1.alpha.(S*),2.alpha.,3.beta.]]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H35 N7 O4
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 81:115149 Puromycin analogs. Ribosomal binding with diastereomeric carbocyclic puromycin analogs. Vince, Robert; Daluge, Susan (Coll. Pharm., Univ. Minnesota, Minneapolis, Minn., USA). J. Med. Chem., 17(6), 578-83 (English) 1974. CODEN: JMCMAR.
 AB Of 7 title compds. prepd. and found active in the inhibition of poly-UC-directed polyphenylalanine formation in an Escherichia coli cell-free system, 6-(dimethylamino)-9-[(R)-[(2R)-hydroxy-(3R)-(L-phenylalanyl)amino]cyclopentyl]purine (I) [52661-26-4] gave 98.6% inhibition at 10⁻⁴M. I was prepd. from 3-acetamidocyclopentene [52661-16-2] by epoxidn., opening of the epoxide with NaN₃ [26628-22-8], followed by redn. to the azido alc., resoln. via tartrate formation, introduction of the purine moiety, and coupling with the amino acid. The relation of structure of the various aminoacyl analogs to activity was discussed.

L31 ANSWER 117 OF 119 REGISTRY COPYRIGHT 2002 ACS
 RN 51034-62-9 REGISTRY
 CN L-Phenylalanine, N-[(phenylmethoxy)carbonyl]-, 2-[1-(6-amino-9H-purin-9-yl)-2-hydroxyethoxy]-3-hydroxypropyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)
 MF C27 H30 N6 O7
 LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 80:34682 Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. XVII. L-Phenylalanine esters of open-chain analog of adenosine as substrates for ribosomal peptidyl transferase. Chladek, Stanislav; Ringer, David; Zemlicka, Jiri (Michigan Cancer Found., Detroit, Mich., USA). Biochemistry, 12(25), 5135-8 (English) 1973. CODEN: BICHAW.
AB The chem. synthesis of the open-chain analogs of 2'-O-(L-phenylalanyl)adenosine (I) and 3'-O-(L-phenylalanyl)adenosine (II) and 2',3'-bis-O-(L-phenylalanyl)adenosine (III) is described. Compds. I and III were active in the release of N-Ac-Phe-tRNA catalyzed by ribosomes: at 0.1mM, compd. I released 8% and II, 12% and at 1mM, 40 and 50%, resp., of the amt. of AcPhe released by 2' (3')-O-(L-phenylalanyl)adenosine. The results indicate that peptidyltransferase requires the 3'-aminoacyl deriv. and that an intact furanose ring is of importance for the peptide transfer reaction.

L31 ANSWER 118 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 31518-53-3 REGISTRY
CN Adenosine, 5'-[2-(carboxyamino)acetamido]-2',5'-dideoxy-, benzyl ester (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N7 O5
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Searched by: Mary Hale 308-4258 CM-1 12D16


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 74:112423 Nucleoside peptides. I. Synthesis of 5'-deoxy-5'-amino-5'-N-aminoacyl peptide derivatives of guanosine, adenosine, and 2'-deoxyadenosine and their effect of cell-free protein synthesis. Robins, Morris J.; Simon, Lionel N.; Stout, Mason G.; Ivanovics, George A.; Schweizer, Martin P.; Rousseau, Robert J.; Robins, Roland K. (ICN Nucl. Acid Res. Inst., Irvine, Calif., USA). J. Amer. Chem. Soc., 93(6), 1474-80 (English) 1971. CODEN: JACSAT.

AB Several 5'-N-aminoacyl-5'-amino-5'-deoxy- and 5'-amino-2',5'-dideoxy-9-.beta.-D-ribofuranosylpurine nucleoside peptides were synthesized which represent a new class of peptides were coupled to the corresponding purine 5'-amino-5'-deoxynucleoside deriv. by the active ester and dicyclohexylcarbodi-imide methods of peptide formation. These compds. were studied to det. their effect on poly-U directed polyphenylalanine synthesis. In instances where the aminoacyl moiety was L-phenylalanine and the nucleoside was either 5'-amino-5'-deoxyadenosine or 5'-amino-2',5'-dideoxyadenosine, inhibition of poly-U directed polyphenylalanine synthesis was obsd. at high concns. and significant stimulation was obsd. at lower concns. Chem. and biol. properties of this new type of nucleoside peptide are discussed. PMR data indicate that 5'-N-(L-phenylalanyl)-5'-amino-2',5'-dideoxyadenosine exists in soln. in a folded conformation with Ph and adenine ring stacking.

L31 ANSWER 119 OF 119 REGISTRY COPYRIGHT 2002 ACS
RN 31518-49-7 REGISTRY
CN Adenosine, 5'-[2-(carboxyamino)-4-methylvaleramido]-2',5'-dideoxy-, benzyl ester, L- (8CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H31 N7 O5
LC STN. Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 74:112423 Nucleoside peptides. I. Synthesis of 5'-deoxy-5'-amino-5'-N-aminoacyl peptide derivatives of guanosine, adenosine, and 2'-deoxyadenosine and their effect of cell-free protein synthesis. Robins, Morris J.; Simon, Lionel N.; Stout, Mason G.; Ivanovics, George A.; Schweizer, Martin P.; Rousseau, Robert J.; Robins, Roland K. (ICN Nucl. Acid Res. Inst., Irvine, Calif., USA). J. Amer.

Searched by: Mary Hale 308-4258 CM-1 12D16

Chem. Soc., 93(6), 1474-80 (English) 1971. CODEN: JACSAT.

AB Several 5'-N-aminoacyl-5'-amino-5'-deoxy- and 5'-amino-2',5'-dideoxy-9-
.beta.-D-ribofuranosylpurine nucleoside peptides were synthesized which
represent a new class of peptides were coupled to the corresponding purine
5'-amino-5'-deoxynucleoside deriv. by the active ester and
dicyclohexylcarbodi-imide methods of peptide formation. These compds.
were studied to det. their effect on poly-U directed polyphenylalanine
synthesis. In instances where the aminoacyl moiety was L-phenylalanine
and the nucleoside was either 5'-amino-5'-deoxyadenosine or
5'-amino-2',5'-dideoxyadenosine, inhibition of poly-U directed
polyphenylalanine synthesis was obsd. at high concns. and significant
stimulation was obsd. at lower concns. Chem. and biol. properties of this
new type of nucleoside peptide are discussed. PMR data indicate that
5'-N-(L-phenylalanyl)-5'-amino-2',5'-dideoxyadenosine exists in soln. in a
folded conformation with Ph and adenine ring stacking.

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	776.75	2235.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-70.21	-152.40

FILE 'CAPLUS' ENTERED AT 13:09:07 ON 02 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 May 2002 VOL 136 ISS 18
FILE LAST UPDATED: 30 Apr 2002 (20020430/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.


L32 35 L31

=> d 11-35 cbib abs hitstr;fil caol;s 131

L32 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS
1995:827456 Document No. 124:87644 Synthesis of enantiomerically pure
5'-aza-noraristeromycin analogs. Ghosh, Arun; Ritter, Allen R.; Miller,
Marvin J. (Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556,

Searched by: Mary Hale 308-4258 CM-1 12D16

GI



I

AB Synthesis of a novel class of enantiomerically pure aza-noraristeromycins, e.g. I, via asym. hetero Diels-Alder reaction, palladium(0)-catalyzed addn. of the sodium salt of adenine, and catalytic osmium tetroxide dihydroxylation, is described.


IT 172323-67-0P 172323-70-5P 172487-61-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of enantiomerically pure aza-noraristeromycin analogs)

RN 172323-67-0 CAPLUS

CN Carbamic acid, [2-[[4-(6-amino-9H-purin-9-yl)-2-cyclopenten-1-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1S-[1.alpha.(R*),4.alpha.]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172323-70-5 CAPLUS


CN Carbamic acid, [(1S)-2-[[[(1S,2R,3S,4R)-4-(6-amino-9H-purin-9-yl)-2,3-dihydroxycyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172487-61-5 CAPLUS
 CN Carbamic acid, [2-[[4-(6-amino-9H-purin-9-yl)-2,3-dihydroxycyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1S-[1.alpha.(R*),2.alpha.,3.alpha.,4.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 172323-69-2P 172323-71-6P 172487-62-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of enantiomerically pure aza-noraristeromycin analogs)
 RN 172323-69-2 CAPLUS
 CN Carbamic acid, [2-[[3-(6-amino-9H-purin-9-yl)cyclopentyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [1R-[1.alpha.(S*),3.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172323-71-6 CAPLUS

CN Carbamic acid, [2-[[6-(6-amino-9H-purin-9-yl)tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [3aR-[3a.alpha.,4.alpha.(S*),6.alpha.,6a.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172487-62-6 CAPLUS



CN Carbamic acid, [2-[[6-(6-amino-9H-purin-9-yl)tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester, [3aS-[3a.alpha.,4.beta.(R*),6.beta.,6a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2002 ACS
 1994:323064 Document No. 120:323064 Synthesis of purine-acridine hybrid
 molecules related to artificial endonucleases. Fkyerat, Abdellatif;
 Demeunynck, Martine; Constant, Jean Francois; Lhomme, Jean (Univ. J.
 Fourier, Grenoble, 38041, Fr.). Tetrahedron, 49(48), 11237-52 (English)
 1993. CODEN: TETRAB. ISSN: 0040-4020.

GI




AB In the course of a program devoted to the synthesis of artificial
 endonucleases, the hybrid mols. I (R = H, NH₂, n = 1, 2) and II (X =
 COCH₂CH₂, CH₂CH₂CO) in which a purine is linked to an aminoacridine by an
 aliph. chain contg. amido or/and amino groups have been prepd. The key
 intermediates are .alpha.-halo-.omega.-amino polyaza chains which may be
 of general use as linkers in bioconjugate chem. I and II recognize and
 cleave selectively abasic sites in DNA with very high efficiency.

IT **155177-51-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (intermediate in prepn. of purine acridine hybrid endonuclease model)

RN 155177-51-8 CAPLUS

CN .beta.-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-.beta.-alanyl-N-[3-(6-
 amino-9H-purin-9-yl)propyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2002 ACS

1994:289415 Document No. 120:289415 Structure-Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3-Selective Adenosine Agonists. Gallo-Rodriguez, Carola; Ji, Xiao-duo; Melman, Neli; Siegman, Barry D.; Sanders, Lawrence H.; Orlina, Jeraldine; Fischer, Bilha; Pu, Quanlong; Olah, Mark E.; et al. (Laboratory of Bioorganic Chemistry, National Institute of Diabetes Digestive Kidney Diabetes, Bethesda, MD, 20892, USA). J. Med. Chem., 37(5), 636-46 (English) 1994. CODEN: JMCMAR. ISSN: 0022-2623.

AB Adenosine analogs modified at the 5'-position as uronamides and/or as N6-benzyl derivs. were synthesized. These derivs. were examd. for affinity in radioligand binding assays at the newly discovered rat brain A3 adenosine receptor and at rat brain A1 and A2a receptors. 5'-Uronamide substituents favored A3 selectivity in the order N-Me > N-Et .apprxeq. unsubstituted carboxamide > N-cyclopropyl. 5'-N-Methyl-N6-benzyladenosine was 37-56-fold more selective for A3 receptors. Potency at A3 receptors was enhanced upon substitution of the benzyl substituent with nitro and other groups. 5'-N-Methyluronamides and N6-(3-substituted-benzyl)adenosines are optimal for potency and selectivity at A3 receptors. A series of 3-(halobenzyl)-5'-N-ethyluronamide derivs. showed the order of potency at A1 and A2a receptors of I .apprx. Br > Cl > F. At A3 receptors the 3-F deriv. was weaker than the other halo derivs. 5'-N-Methyl-N6-(3-iodobenzyl)adenosine displayed a Ki value of 1.1 nM at A3 receptors and selectivity vs. A1 and A2a receptors of 50-fold. A series of methoxybenzyl derivs. showed that a 4-methoxy group best favored A3 selectivity. A 4-sulfobenzyl deriv. was a specific ligand at A3 receptors of moderate potency. An aryl amino deriv. was prepd. as a probe for radioiodination and receptor crosslinking.


IT 152918-10-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and adenosine agonist activity of, structure in relation to)

RN 152918-10-0 CAPLUS


CN Carbamic acid, [2-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-.beta.-D-ribofuranuronoyl]amino]ethyl]-, 1,1-dimethylethyl ester '(9CI) (CA INDEX NAME)

Absolute stereochemistry.



1992:470267 Document No. 117:70267 Preparation of 5-amino group-containing adenosine analogs as immunosuppressants.. Bowlin, Terry L. (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 472181 A2 19920226, 28 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1991-113994 19910821. PRIORITY: US 1990-571042 19900822.

GI



AB The title compds. [I; R = H, Me, Et; Q = (substituted) amino-2-butenyl, (substituted) aminopropyl, (substituted) butynyl, (substituted) aminofluoropropyl, (substituted) aminobutyl, etc.;. cis-N-tert-Butoxycarbonyl-4-chloro-2-butenylamine (prepn. given) was refluxed with 5'-deoxy-5'-(methylamino)-2',3'-isopropylideneadenosine in MeCN contg. K2CO3 and NaI overnight, to give, after deprotection (H2SO4 at room temp. for 2 days), cis-5'-deoxy-5'-(4-amino-2-butenyl)methylaminoadenosine. This at 100 .mu.M showed 64% redn. of cloned interleukin 2-dependent cytolytic T lymphocytes.


IT **128490-17-5P 128490-31-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for immunosuppressants)

RN 128490-17-5 CAPLUS


CN Adenosine, 5'-deoxy-5'-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-propenyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128490-31-3 CAPLUS
 CN Adenosine, 5'-deoxy-5'-[[3-[[{(1,1-dimethylethoxy)carbonyl]amino]-2,2-difluoropropyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2002 ACS
 1990:478901 Document No. 113:78901 Preparation of 5'-deoxy-5'-aminoadenosine derivatives as S-adenosylmethionine decarboxylase inhibitors. Casara, Patrick; Danzin, Charles (Merrell Dow Pharmaceuticals, Inc., USA). Eur. Pat. Appl. EP 351475 A1 19900124, 20 pp. DESIGNATED STATES: R: FR. (English). CODEN: EPXXDW. APPLICATION: EP 1988-401896 19880721.

GI



AB The title compds. [I; R = NR₁ZNH₂; R₁ = H, Me, Et; Z = CV₁V₂C(:CXY)CH₂, CV₁V₂C.tplbond.CCH₂, Q, cis-CV₁V₂CW:CZ₁CH, CV₁V₂CR₂FCH₂, CH₂CH₂CWZ₁CH₂; R₂ = H, F; n = 1, 2; V₁ = H, Me; V₂ = H, CO₂H; W, X, Y, Z = H, F, Cl, Br] are prepd. I are potent and irreversible inhibitors of S-adenosylmethionine decarboxylase, and therefore significantly interfere with the formation of spermine and spermidine, and are useful for treatment of diseases assocd. with the rapid proliferation of normal and transformed cells (no data). I in combination with an ornithine decarboxylase (ODC) inhibitor are useful as postcoital contraceptives and menstruation inducers. Antitumor agents in conjunction with I lower side effects and increase survival time. I alone or in combination with an ODC inhibitor may be used as parasiticides, bactericides, fungicides or virucides. Thus, a soln. of cis-Me₃CO₂CNHCH₂CH:CHCH₂Cl, 5'-deoxy-5'-methylamino-2',3'-

Searched by: Mary Hale 308-4258 CM-1 12D16

isopropylideneadenosine, K₂CO₃, and NaI in MeCN was refluxed overnight to give, after hydrolysis with 1N aq. H₂SO₄, I (R = cis-H₂NCH₂CH:CHCH₂NMe). A total of 9 I were prepd.


IT 128490-17-5P 128490-31-3P 128490-36-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for S-adenosylmethionine decarboxylase inhibitor aminodeoxyadenosine)

RN 128490-17-5 CAPLUS

CN Adenosine, 5'-deoxy-5'-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-propenyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 128490-31-3 CAPLUS

CN Adenosine, 5'-deoxy-5'-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-difluoropropyl]methylamino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128490-36-8 CAPLUS

CN Adenosine, 5'-deoxy-5'-[[5-(1,1-dimethylethoxy)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxo-2-pentenyl]methylamino]-2',3'-O-(1-methylethylidene)-, (Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



L32 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2002 ACS
 1990:36385 Document No. 112:36385 Preparation of griseolic acid diester derivatives for treatment of glaucoma. Kaneko, Masakatsu; Kimura, Misako; Kamokari, Makoto; Yokoyama, Tomihisa; Yamazaki, Mitsuo (Sankyo Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 01146895 A2 19890608 Heisei, 15 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1987-306199 19871202.

GI




AB The title compds. [I; R1, R2 = H, (un)protected OH; R3, R4 = H or R3R4 = bond; R5, R6 = R7CO2CHR8, R9CO2CHR10, Q; R7, R8 = straight chain or branched C1-10 alkyl, C3-10 cycloalkyl; R8, R10 = H, straight chain or branched C1-10 alkyl, C3-10 cycloalkyl; R11 = straight chain or branched C1-10 alkyl, C3-10 cycloalkyl, C6-10 aryl] and its salts which show good activity for lowering the intraocular pressure of eye and are useful for treatment of glaucoma, are prepd. Thus, MeCN was added to griseolic acid followed by 1,8-diazabicyclo[5.4.0]-7-undecene with stirring under N. To the resulting mixt., Me3CCO2CH2I was added under ice-cooling and the mixt. was stirred 1 h at room temp. to give 60.5% griseolic acid 8',9'-dipivaloyloxymethyl ester (II). II 0.002% soln. (50 .mu.L) in 0.4% NaCl was applied twice to a rabbit's eye, the intraocular pressure was lowered by a factor of 0.77 over that of the eye treated with 0.5% timolol. An ophthalmic soln. (100 mh, pH 7.0) contg. II 0.002, Na2HPO4 0.716, NaH2PO4 0.728, NaCl 0.400, p-HOC6H4CO2Me 0.026, p-HOC6H4CO2Pr 0.014 g, q.s. H2O, and q.s. NaOH.

IT 124464-13-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of glaucoma)

RN 124464-13-7 CAPLUS


CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-1,5-dideoxy-6-C-[[1-[[[(1-methylethoxy)carbonyl]oxy]ethoxy]carbonyl]-, 1-[[[(1-methylethoxy)carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME).



L32 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS

1990:21258 Document No. 112:21258 Griseolic acid monesters, their preparation and use in treatment of ophthalmic disorders. Kaneko, Masakatsu; Kimura, Misako; Kamokari, Makoto; Yokoyama, Tomihisa; Yamazaki, Mitsuo; Hirai, Koichi; Sato, Susumu; Yasumoto, Takashi (Sankyo Co., Ltd., Japan). Eur. Pat. Appl. EP 319316 A2 19890607, 112 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1988-311441 19881202. PRIORITY: JP 1987-306200 19871202; JP 1988-162882 19880630.

GI



AB The title compds. [I; R1, R2 = H, (un)protected HO; R3, R4 = H or R3R4 = bond; one of R5, R6 = H, and the other = a carboxy-protecting group removable in the biochem. environment of the human eye], useful for the treatment of ophthalmic disorders, were prepd. To a soln. of 5 g griseolic acid in Me2SO was added 2.7 mL 1,8-diazabicyclo[5.4.0]-7-undecene under N followed successively by MeCN and 3.83 g iodomethyl pivalate with ice-cooling and then the mixt. was allowed to react at room temp. for 5 h to give, after aq. processing and purifn. by chromatog., 10.6% 9'-pivaloyloxymethyl griseolate (II). Instillation of II (50 .mu.L of 1% w/v soln.) into the anesthetized left or right eye of rabbits reduced the intraocular pressure by 2.38 mmHg over the other untreated eye

Searched by: Mary Hale 308-4258 CM-1.12D16


vs. 1.0 mmHg for timolol. An ophthalmic soln. contg. II 1.0, disodium phosphate 0.716, monosodium phosphate 0.728, NaCl 0.400, Me p-hydroxybenzoate 0.026, Pr p-hydroxybenzoate 0.014 g, sterile purified H₂O q.s., and NaOH q.c. was prepd.

IT 124254-40-6P 124254-63-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for treatment of ophthalmic disorders)


RN 124254-40-6 CAPLUS

CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-6-C-carboxy-1,5-dideoxy-, 8-[1-[(1-methylethoxy)carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME)



RN 124254-63-3 CAPLUS


CN .alpha.-L-talo-Oct-4-enofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3,6-anhydro-6-C-carboxy-1,5-dideoxy-, 8-[1-[(1-methylethoxy)carbonyl]oxy]ethyl ester, 7-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)



L32 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2002 ACS

1989:423916 Document No. 111:23916 Preparation of 5-deoxy-5-O-substituted adenosine derivatives as inhibitors of S-adenosylmethionine decarboxylase. Secrist, John A., III (Southern Research Institute, USA). U.S. US 4794174 A 19881227, 10 pp. (English). CODEN: USXXAM. APPLICATION: US 1987-13061 19870210.

GI



AB The title adenosine derivs. [I; X = NH, NMe, S, MeS⁺; n = 2-4; Z = NHC(:NH)NH₂, NHC(:NH)NHNH₂, NHCONHNH₂, NHNH₂, NHCON(NO)Me, NHC(S)NHNH₂] were prep'd. as S-adenosylmethionine decarboxylase (AdoMet-DC) inhibitors. Reaction of 2',3'-O-isopropylidene-5'-O-tosyladenosine with MeNH(CH₂)₃OH in DMF for 40 h gave 72% 5'-deoxy-2',3'-O-isopropylidene-5'-[N-methyl-N-(3-hydroxypropyl)]amino adenosine which was treated with Me₃CO₂CN:NCO₂CMe₃ and Ph₃P in THF to give 75% 5'-deoxy-2',3'-isopropylidene-5'-[N-methyl-N-[3-[1,2-bis(1,1-dimethylethoxy)carbonyl]hydrazino]propyl]]aminoadenosine. Hydrolysis of the latter in a 1:1 mixt. of dioxane and 1 M H₂SO₄ at 70.degree. for 2 h gave 65% I (Z = NHNH₂, n = 3, X = NMe) (II). II inhibited AdoMet-DC with an ID₅₀ of 0.08 .mu.M.


IT **121032-16-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for S-adenosylmethionine decarboxylase inhibitor)

RN 121032-16-4 CAPLUS


CN Adenosine, 5'-[[3-[1,2-bis[(1,1-dimethylethoxy)carbonyl]hydrazino]propyl]methylamino]-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



6-amino- and 6-dimethylamino-9-(aminoacylamidobenzyl)purines. Kelley, James L.; Miller, Carl A.; Selway, John W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA). Eur. J. Med. Chem., 23(4), 319-23 (English) 1988. CODEN: EJMCA5. ISSN: 0223-5234. OTHER SOURCES: CASREACT 110:154822.

GI




AB Title compds. I (R = H, Me; R1 = o-, n-, p-H-Gly-NH, H-Leu-NH, H-Phe-NH) were prepd. from the nitrobenzylpurines. Only I (R = Me, R1 = m-H-Phe-NH) and the intermediate I (R = Me, R1 = m - NH2) had activity against rhinovirus 1B.

IT 119805-67-3P 119805-68-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and deblocking of)


RN 119805-67-3 CAPLUS

CN Carbamic acid, [2-[[2-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 119805-68-4 CAPLUS

CN Carbamic acid, [1-[[[4-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 119805-55-9P 119805-60-6P 119830-84-1P
119830-85-2P

Searched by: Mary Hale 308-4258 CM-1 12D16

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrogenolysis of)


RN 119805-55-9 CAPLUS

CN Carbamic acid, [2-[[4-[[6-(dimethylamino)-9H-purin-9-yl]methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 119805-60-6 CAPLUS

CN Carbamic acid, [1-[[[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 119830-84-1 CAPLUS

CN Carbamic acid, [2-[[4-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 119830-85-2 CAPLUS

CN Carbamic acid, [2-[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 119805-61-7P 119805-77-5P

Searched by: Mary Hale 308-4258 CM-1 12D16

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and virucidal activity of)

RN 119805-61-7 CAPLUS


CN Carbamic acid, [1-[[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 119805-77-5 CAPLUS

CN Carbamic acid, [1-[[[3-[(6-amino-9H-purin-9-yl)methyl]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2002 ACS

1989:154786 Document No. 110:154786 The chemistry of 2',3'-seconucleosides. III. Synthesis and reactions of purine-2',3'-secoribonucleosides. Beaton, Graham; Jones, A. Stanley; Walker, Richard T. (Chem. Dep., Univ. Birmingham, Birmingham, B15 2TT, UK). Tetrahedron, 44(20), 6419-28 (English) 1988. CODEN: TETRAB. ISSN: 0040-4020. OTHER SOURCES: CASREACT 110:154786.


AB 5'-O-Protected purine-ribonucleosides were oxidized with periodate to give dialdehydes which upon redn. with sodium borohydride gave 5'-O-protected purine-2',3'-secoribonucleosides, which were converted into their 2',3'-di-O-mesyl derivs.. These were converted into 2',3'-disubstituted-2',3'-dideoxy derivs. and because the 2'-O-mesyl group was significantly less reactive than the 3'-O-mesyl group, selective substitution at either the 2' or 3'-positions was achieved. As an example of the latter procedure, syntheses of 3'-amino-3'-deoxy-2',3'-secoadenosine and of 3'-deoxy-2',3'-secoinosine are described. The former compd. was used as the starting material for the synthesis of a secopuromycin analog.

IT 119898-90-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrogenolysis of)

RN 119898-90-7 CAPLUS


CN Carbamic acid, [2-[[2-[1-(6-amino-9H-purin-9-yl)-2-hydroxyethoxy]-3-hydroxypropyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, [1S-[1R*,2[R*(S*)]]]- (9CI) (CA INDEX NAME)



L32 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2002 ACS

1987:214262 Document No. 106:214262 Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation. Lever, O. William, Jr.; Vestal, B. Randall (Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA). J. Heterocycl. Chem., 23(3), 901-3 (English) 1986. CODEN: JHTCAD. ISSN: 0022-152X. OTHER SOURCES: CASREACT 106:214262.

GI



AB Twelve title compds. I (R = NO, NO₂; n = 2, 3, 4, 5, 6, 7) were prepd. from the corresponding H₂N(CH₂)_nCO₂H by sequential N-benzyloxycarbonylation with PhCH₂OCOC₂H₅, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzyloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitrosoisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.


IT 108257-19-8P 108257-20-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, intermediate in synthesis of bridged isocytosine-adenosine compds.)

RN 108257-19-8 CAPLUS


CN Adenosine, 5'-deoxy-5'-[[1-oxo-3-[[(phenylmethoxy) carbonyl] amino] propyl] amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 108257-20-1 CAPLUS
 CN Adenosine, 5'-deoxy-5'-[[1-oxo-4-[[(phenylmethoxy) carbonyl] amino] butyl] amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2002 ACS
 1986:479332 Document No. 105:79332 Synthesis of nucleic acid analogs of natural nucleopeptides. Ryabtseva, O. N.; Semiletov, Yu. A.; Korshunova, G. A.; Shvachkin, Yu. P. (Mosk. Gos. Univ., Moscow, USSR). Zh. Obshch. Khim., 55(11), 2633-4 (Russian) 1985. CODEN: ZOKHA4. ISSN: 0044-460X.
 AB Fifteen analogs of H-.gamma.-Glu-X-Ual-OH [I; Ual = L-.beta.-(uracilyl-N1)-.alpha.-alanine residue; X = null or Phe], in which Ual is replaced by .beta.-(thyminy-N1)-.alpha.-alanine or .beta.-(adeniny-N9)-.alpha.-alanine, were prepd. by the soln. method using pentafluorophenyl esters for peptide couplings. I have been previously isolated from seeds of Fagus silvatica.
 IT 103582-76-9P 103582-77-0P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 103582-76-9 CAPLUS
 CN L-Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[N-[(1,1-dimethylethoxy) carbonyl]-L-.gamma.-glutamyl]-L-phenylalanyl]-, 1-methyl 1'-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 103582-77-0 CAPLUS

CN L-Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-.gamma.-glutamyl]-L-phenylalanyl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L32 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS

1986:479329 Document No. 105:79329 Structure activity relationships of synthetic antibiotic analogs of chryscandin. Komori, Tadaaki; Sakane, Kazuo; Setoi, Hiroyuki; Kawai, Yoshio; Teraji, Tsutomu; Kohsaka, Masanobu; Imanaka, Hiroshi (Explor. Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan). J. Antibiot., 38(9), 1182-203 (English) 1985. CODEN: JANTAJ. ISSN: 0021-8820.

GI



AB Chryscandin (I) and 98 analogs, e.g. II (R = OH, NHNH₂, etc.; R₁ = H-Phe, H-Cys, etc.), were prepd. and their antibacterial activities were detd. Thus, Z-Tyr(Me)-OH (Z = PhCH₂O₂C) was condensed with amino nucleoside III (R₂ = H) by DCC/N-hydroxysuccinimide to give III [R₂ = Z-Tyr(Me)], which was deblocked by BuNH₂ and hydrogenolysis to give I. II (R = OH, R₁ = H-Cys) showed the highest efficacy against *Candida albicans*.


IT 103618-92-4P 103618-93-5P 103618-96-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deblocking of)

RN 103618-92-4 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 103618-93-5 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Searched by: Mary Hale 308-4258 CM-1 12D16



RN 103618-96-8 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-,
ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 103618-94-6


RL: RCT (Reactant)

(reaction of, with aminoethyl di-Ph phosphite)

RN 103618-94-6 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]-,
(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L32 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2002 ACS

1986:122620 Document No. 104:122620 Purine acyclic nucleosides.

6-Dimethylamino-9-[(2-phenylalanylamido-1-substituted-ethoxy)methyl]purines as candidate antivirals. Kelley, James L.; Selway, J. W. T.; Schaeffer, Howard J. (Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA). J. Pharm. Sci., 74(12), 1302-4 (English) 1985. CODEN: JPMSAE. ISSN: 0022-3549.

GI



I, R=CH(R¹)CH₂NH₂

II, R=CH(R¹)CH₂NHCOCH(CH₂Ph)NHR²


AB The title compds., which are puromycin acyclic analogs, and their intermediates (I and II; R¹ = Me, cyclopentyl, or Ph; II; R² = H or PhCH₂CO₂) were prepd., in several steps starting with the phthaloylation of 1-substituted-2-aminoethanols, and test for antiviral activity (adenovirus, herpes simplex 1, vaccinia, influenza virus, etc.) in vitro. The intermediate II (R¹ = cyclopentyl and R² = PhCH₂CO₂) [75128-61-9] was active against 2 of the strains tested.

IT 75128-66-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antiviral activity of)

RN 75128-66-4 CAPLUS


CN Carbamic acid, [2-[[2-[[6-(dimethylamino)-9H-purin-9-yl]methoxy]propyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2002 ACS

1984:631024 Document No. 101:231024 Tetrahydrofurancarboxylic acid derivatives. (Fujisawa Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 59098099 A2 19840606 Showa, 50 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1983-206816 19831102. PRIORITY: GB 1982-31663 19821105; GB 1983-3473 19830208.

GI



AB One hundred and twenty seven THF carboxylic acid derivs. I [R = (substituted) amino; R1 = (amino acyl) amino; R2 = (protected) carboxy; R3 = H, alkyl] were prepd., e.g., by acylation of I (R1 = NH2). Thus, stirring a mixt. of 2.31 g I (R = R1 = NH2, R2 = CO2Et, R3 = H), 75 mL H2O, 2.74 g Boc-Cys(Me)ONSu (Boc = Me3CO2, NSu = succinimido), and 75 mL THF at room temp. for 2 h gave 1.76 g I [R = NH2, R1 = Boc-Cys(Me)-NH, R2 = CO2Et, R3 = H]. I [R, R1, R2, R3 = NH2, Met-NH, CO2H, H; NH2, H-Cys(CH2CH:CH2)-NH, CO2H, H] inhibited bacterial growth at 4 and 2 .mu.g/mL, resp.


IT 93095-81-9P 93095-82-0P 93095-85-3P
 93095-86-4P 93095-92-2P 93095-93-3P
 93095-94-4P 93095-97-7P 93096-08-3P
 93096-10-7P 93096-11-8P 93096-12-9P
 93096-13-0P 93096-24-3P 93096-26-5P
 93096-27-6P 93096-28-7P 93096-29-8P
 93096-30-1P 93096-31-2P 93096-32-3P
 93096-50-5P 93096-51-6P 93096-52-7P
 93096-53-8P 93096-54-9P 93096-55-0P
 93096-56-1P 93096-58-3P 93096-59-4P
 93096-69-6P 93096-71-0P 93096-87-8P
 93096-88-9P 93096-89-0P 93096-90-3P
 93096-91-4P 93096-92-5P 93096-93-6P
 93096-94-7P 93096-95-8P 93096-96-9P
 93096-97-0P 93096-98-1P 93096-99-2P
 93097-00-8P 93097-01-9P 93097-02-0P
 93097-03-1P 93097-04-2P 93097-05-3P
 93097-06-4P 93097-07-5P 93097-08-6P
 93097-09-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antibacterial activity of)


RN 93095-81-9 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-(methylsulfinyl)-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93095-82-0 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfinyl)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 93095-85-3 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfonyl)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93095-86-4 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylsulfonyl)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


RN 93095-94-4 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[1-[(1,1-dimethylethoxy)carbonyl]-1H-imidazol-4-yl]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 93095-97-7 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[2-[(trifluoroacetyl)amino]-5-thiazolyl]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 93096-08-3 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-


(9CI) (CA INDEX NAME)



RN 93096-10-7 CAPLUS

CN Pentofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-N-hydroxy-


(9CI) (CA INDEX NAME)



RN 93096-11-8 CAPLUS

CN Phosphonic acid, [2-[[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pe


ntofuranuronoyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 93096-12-9 CAPLUS


CN Glycine, N-[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pe

ntofuranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 93096-13-0 CAPLUS

CN Ethanesulfonic acid, 2-[[1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]pentofuranuronoyl]amino]- (9CI) (CA INDEX NAME)




RN 93096-24-3 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-2-O-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-26-5 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(1H-pyrrol-2-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-27-6 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-thienyl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-28-7 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-amino-4-pyrimidinyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-29-8 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(5-amino-1,2,4-thiadiazol-3-yl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 93096-30-1 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(4-pyridinyl)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 93096-31-2 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[[(2-amino-4-thiazolyl)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 93096-32-3 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]- (9CI)
(CA INDEX NAME)



RN 93096-50-5 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-[[[4-(dimethylamino)phenyl]methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)






RN 93096-51-6 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-(ethylthio)-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-52-7 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-cyclohexen-1-ylthio)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-53-8 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-[(1-methylethyl)thio]-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 93096-54-9 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-[(2,3-dichloro-2-propenyl)thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-55-0 CAPLUS

CN Pentofuranuronic acid, 3-[[3-[[[4-(acetyloxy)phenyl]methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dioxo-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A






RN 93096-56-1 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(2-ethoxy-2-oxoethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-58-3 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-4-(2-propenylthio)butyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 93096-59-4 CAPLUS


CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-(methylthio)-1-oxopentyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 93096-69-6 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(1-phenylethyl)thio]propyl]amino]-


, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-71-0 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[(4-methoxyphenyl)methyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 93096-87-8 CAPLUS


Searched by: Mary Hale 308-4258 CM-1 12D16

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-88-9 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(methylthio)-1-oxopropyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 93096-89-0 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-(methylthio)-1-oxobutyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-90-3 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenylthio)propyl]amino]- (9CI) (CA INDEX NAME)




RN 93096-91-4 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(phenylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-92-5 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(1,1-dimethylethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-93-6 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-propenylthio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-94-7 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-propynylthio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-95-8 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(3-phenyl-2-propenyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 93096-96-9 CAPLUS

CN Pentofuranuronic acid, 3-[[3-[[[(acetylamino)methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)





RN 93096-97-0 CAPLUS



CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[(4-methylphenyl)methyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-98-1 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[4-chlorophenyl)methyl]thio]-2-[[1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 93096-99-2 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-[[2-chlorophenyl)methyl]thio]-2-[[1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 93097-00-8 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93097-01-9 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(2-thienylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93097-02-0 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[(2-furanylmethyl)thio]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 93097-03-1 CAPLUS

CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(2-pyridinylthio)propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


CCOC(=O)C1OC(NC(=O)CCNC(=O)OCC)C(O)C1Nc2nc(N)cnc2

PAGE 2-A




RN 93097-05-3 CAPLUS
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(3-pyridinylmethyl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 93097-06-4 CAPLUS
CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[(tetrahydro-2H-pyran-2-yl)thio]propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 93097-07-5 CAPLUS
 CN Pentofuranuronic acid, 3-[[3-[[[5-(acetylamino)-1,2,4-thiadiazol-3-yl]methyl]thio]-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 93097-08-6 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[[1-[(1,1-dimethylethoxy)carbonyl]-5-methyl-1H-imidazol-4-yl]methyl]thio]-1-oxopropyl]amino]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 93097-09-7 CAPLUS
 CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-

dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenyldithio)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 93095-91-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 93095-91-1 CAPLUS



CN Pentofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-(phenyldithio)propyl]amino]- (9CI)
(CA INDEX NAME)



L32 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2002 ACS

1983:522910 Document No. 99:122910 Tetrahydrofuran carboxylic acid derivatives and pharmaceutical compositions thereof. Yamashita, Michio; Komori, Tadaaki; Hosoda, Junji; Kawai, Yoshio; Uchida, Itsuro; Kohsaka, Masanobu; Imanaka, Hiroshi; Sakane, Kazuo; Setoi, Hiroyuki; Teraji, Tsutomu (Fujisawa Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 71926 A1 19830216, 126 pp. DESIGNATED STATES: R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1982-106942 19820731. PRIORITY: GB 1981-24352 19810810.

GI



AB Title compds. I (R = NH₂ or protected NH₂; R₁ = NH₂ or acylamino; R₂ = CO₂H or protected CO₂H) were prepd. as antimicrobial agents. Thus, FR-48736 substance (II) was produced by the fermn. of *Chrysosporium pannorum* ATCC 20617; the structure of II was detd. by an anal. of its phys. and chem. properties and by chem. degrdn. The chem. synthesis of II was achieved by hydrogenating ribofuranuronic acid III (R₃ = Bz, R₄ = azido) (IV) over Pd/C to give III (R₃ = Bz, R₄ = NH₂), which was coupled with Z-Tyr(Me)-OH (Z = PhCH₂O₂C) by DCC/N-hydroxysuccinimide (HONSu) to give III [R₃ = Bz, R₄ = Z-Tyr(Me)-NH], which was debenzoylated by refluxing in MeOH/BuNH₂ and then Z-deblocked by hydrogenolysis over Pd/C in the presence of HCl to give II.2HCl. IV was prepd. in several steps from 3-azido-3-deoxy-1,2-O-isopropylidene- α -D-ribofuranose. Analogs of II were prepd., e.g., IV was coupled with Z-Phe-ONSu to give III (R₃ = Bz, R₄ = Z-Phe-NH), which was debenzoylated and then Z-deblocked to give III (R₃ = H, R₄ = H-Phe-NH) (V). V exhibited antimicrobial activity against *Candida albicans* OUT6004 with a min. inhibitory concn. of 31 mcg/mL.


IT **86937-99-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and condensation with phenylalanine ester)

RN 86937-99-7 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-methoxyphenyl)-1-oxopropyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 86937-32-8P 86937-34-0P 86937-35-1P
 86937-36-2P 86937-39-5P 86937-40-8P
 86937-71-5P 86937-73-7P 86937-75-9P
 86937-78-2P 86937-81-7P 86937-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and deblocking of)

RN 86937-32-8 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[3-
 [(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-34-0 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-
 [[[(1,1-dimethylethoxy)carbonyl]amino]phenylacetyl]amino]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 86937-35-1 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-36-2 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-methoxy-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-39-5 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-1-[[1-oxo-2-[[(phenylmethoxy) carbonyl] amino] propyl] amino]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-40-8 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[1-oxo-3-[[(phenylmethoxy) carbonyl] amino] propyl] amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-71-5 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(4-chlorophenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-73-7 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(3-chlorophenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-75-9 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-3-[[3-(2-chlorophenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]-1,3-dideoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-78-2 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-81-7 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-nitrophenyl)-1-oxopropyl]amino]-2-oxo-1,3-dihydroisobenzimidazole-4-carboxylate], ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 86937-83-9 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]propoxy]phenyl]-1-oxopropyl]amino]-2-oxo-1,3-dihydroisobenzimidazole-4-carboxylate], ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t


IT **86937-95-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and partial deblocking of)

RN 86937-95-3 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
[[[(1,1-dimethylethoxy)carbonyl]amino]-1,5-dioxo-5-
(phenylmethoxy)pentyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 86937-85-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sapon. of)

RN 86937-85-1 CAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1,3-dideoxy-3-[[2-
[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[4-(2-methoxy-2-oxoethoxy)phenyl]-
1-oxopropyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L32 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2002 ACS

1982:85942 Document No. 96:85942 Acyclic puromycin analogs:

9-[(2-phenylalanylamidoethoxy)methyl]adenine and 9-(3-
phenylalanylamidopropyl)adenine. Kelley, James L.; Miller, Carl A.;
Schaeffer, Howard J. (Wellcome Res. Lab., Research Triangle Park, NC,
27709, USA). J. Pharm. Sci., 70(10), 1169-71 (English) 1981. CODEN:
JPMSAE. ISSN: 0022-3549.

GI

Searched by: Mary Hale 308-4258 CM-1 12D16



AB Puromycin analog I (R = H, X = O) (II) was prepd. by treating adenine with phthalimide III, deblocking the resulting adenine deriv. IV (R1R2 = phthaloyl) by hydrazinolysis, condensing the resulting IV (R1 = R2 = H) with Z-DL-Phe-OH (Z = PhCH2O2C) by ClCO2Et, and Z-deblocking the resulting I (R = Z, X = O) by hydrogenolysis. I (R = H, X = bond) (V) was prepd. by treating adenine with Z-DL-Phe-NH(CH2)3Br and Z-deblocking the resulting I (R = Z, X = bond) by HBr/HOAc. II and V were tested for inhibition of in vitro protein synthesis and for antiviral and antibacterial activities.

IT **80613-30-5P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrogenolysis of)

RN 80613-30-5 CAPLUS

L32 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2002 ACS

1982:45905 Document No. 96:45905 5'-Chloropuromycin. Inhibition of protein synthesis and antitrypanosomal activity. Vince, Robert; Lee, Heejoo; Narang, A. S.; Shiota, Frances N. (Coll. Pharm., Univ. Minnesota, Minneapolis, MN, 55455, USA). J. Med. Chem., 24(12), 1511-14 (English) 1981. CODEN: JMCMAR. ISSN: 0022-2623.

GI



AB I [80362-00-1] and II [43157-40-0], puromycin derivs., were synthesized and tested for their ability to inhibit protein formation in vitro and for their antitrypanosomal activity in mice. Both I and II inhibited protein formation by acting as substrates at the peptidyltransferase site of

Searched by: Mary Hale 308-4258 CM-1 12D16

ribosomes, whereas only I exhibited significant antitrypanosomal activity in mice. In rats, the aminonucleosides released by the in vivo hydrolysis of I and II exhibited no nephrotoxicity, whereas the corresponding aminoglycoside of puromycin caused severe nephrotoxic manifestations.


IT 80361-99-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and deprotection of)

RN 80361-99-5 CAPLUS

CN Adenosine, 5'-chloro-3',5'-dideoxy-3'-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-methoxyphenyl)-1-oxopropyl]amino]-N,N-dimethyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L32 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2002 ACS

1980:586414 Document No. 93:186414 Compositions for treating viral infections and guanine acyclic nucleosides. Schaeffer, Howard J. (Burroughs Wellcome Co., USA). U.S. US 4199574 19800422, 14 pp. Cont.-in-part of U.S. Ser. No. 608,263, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1976-662900 19760301.

GI



AB Purines I [Z = S, O; R = NH₂; R₁ = OH; R₂ = H, alkyl, hydroxyalkyl; R₃ = H, alkyl, hydroxyalkyl, benzyloxyalkyl, Ph; R₄ = H, OH, alkyl; R₅ = H, OH, NH₂, alkyl, hydroxyalkyl, BzO, benzoyloxyalkyl, PhCH₂O, OSO₂NH₂, OP(O)(OH)₂, carboxypropionyloxy, AcO] were prepd. by different methods; I (R = R₁ = NH₂, Z = O, R₅ = OH, R₂ = R₃ = R₄ = H), which showed antiviral activity, was among the compds. prepd. 6-Chloropurine was alkylated to give 6-chloro-9-(2-benzoyloxyethoxymethyl)purine, and ammonolysis of the product gave 9-(2-hydroxyethoxymethyl)adenine.


IT 75128-53-9P 75128-66-4P

Searched by: Mary Hale 308-4258 CM-1 12D16

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 75128-53-9 CAPLUS

CN Carbamic acid, [2-[[2-[(6-amino-9H-purin-9-yl)methoxy]ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 75128-66-4 CAPLUS


CN Carbamic acid, [2-[[2-[[6-(dimethylamino)-9H-purin-9-yl]methoxy]propyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2002 ACS

1980:129239 Document No. 92:129239 Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamides. Prasad, Raj Nandan; Bariana, Dilbagh S.; Fung, Anthony; Savic, Milica; Tietje, Karin; Stein, Herman H.; Brondyk, Harold; Egan, Richard S. (Org. Chem. Res., Abbott Lab., Ltd., Montreal, PQ, H3C 3K6, Can.). J. Med. Chem., 23(3), 313-19 (English) 1980. CODEN: JMCMAR. ISSN: 0022-2623.

GI



AB About 35 adenosinecarboxamides I [R = H, R1 = Me, Et, PhOCH₂CH₂, Et₂NCH₂CH₂, cyclopropyl, CH₂:CHCH₂, Ph, adamantyl, etc.; R = R1 = CH₂:CHCH₂; or (RNR1) = piperidino, morpholino, etc.] and several analogs of I contg. N1-oxide function or 2',3'-substituents were prepd. from II. II was chlorinated with SOCl₂, the acid chloride was amidated, and the product was deisopropylidenated to give I. Alternatively II was deisopropylidenated and then converted into the ClCH₂CH₂ ester, which was amidated to give I. All the compds. prepd. were evaluated for coronary sinus PO₂ activity in dogs (extensive data given). ¹H-NMR spectra of some of the compds. were examd. and conformations are discussed.


IT **72758-45-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cardiovascular properties of)

RN 72758-45-3 CAPLUS

CN Benzoic acid, 2-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-.beta.-D-ribofuranuronoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2002 ACS

1979:575710 Document No. 91:175710 Nucleoamino acids and nucleopeptides.

IV. Synthesis of oligonucleopeptides containing uracilyl-N1-.alpha.-alanine and adenylyl-N9-.alpha.-alanine residues. Olsuf'eva, E. N.; Shvachkin, Yu. P. (Mosk. Gos. Univ., Moscow, USSR). Zh. Obshch. Khim., 49(5), 1147-51 (Russian) 1979. CODEN: ZOKHA4. ISSN: 0044-460X.


AB Tripeptides incorporating .beta.-(1-uracilyl)alanine (H-Ual-OH) and .beta.-(9-adenylyl)alanine (H-Aal-OH) were prepd., using activated derivs. of these nucleoamino acids. Thus, Boc-Ual-OC₆H₄NO₂-p (Boc = CO₂CMe₃) reacted with H-Ual-Ala-OMe to give Boc-Ual-Ual-Ala-OMe. Reaction of Boc-Aal-OH with N-hydroxysuccinimide gave the activated ester, which reacted with H-Aal-Ala-OMe or H-Aal-Aal-OEt to give Boc-Aal-Aal-Ala-OMe and Boc-(Aal)₃-OEt, resp. The protective groups were removed from these peptides by treatment with 4N HCl in 2:1 dioxane-EtOH.

IT **58328-53-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deblocking of)

RN 58328-53-3 CAPLUS

CN Alanine, 3-(6-amino-9H-purin-9-yl)-N-[N-[3-(6-amino-9H-purin-9-yl)-N-[(1,1-dimethylethoxy)carbonyl]alanyl]-L-alanyl]-, ethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2002 ACS

1976:90565 Document No. 84:90565 Homo- and heterotripeptides containing nucleic bases in the side chains. Shvachkin, Yu. P.; Olsuf'eva, E. N. (Mosk. Gos. Univ. im. Lomonosova, Moscow, USSR). Zh. Obshch. Khim., 45(10), 2351-2 (Russian) 1975. CODEN: ZOKHA4.


AB [In this abst. Ala(3-A) = 3-(6-amino-9H-pyrimidin-9-yl)alanine residue, and Ala(3-U) = 3-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)alanine residue]. Me3CO2C-Ala(3-U)-Ala(3-U)-Ala-OMe, Me3CO2C-Ala(3-A)-Ala(3-A)-Ala-OMe, Me3CO2C-Ala(3-A)-Ala(3-U)-Ala(3-A)-OEt, Me3CO2C-Ala(3-A)-Ala-Ala(3-A)-OEt, Me3CO2C-Ala(3-A)-Ala(3-A)-Ala(3-A)-OEt, Ala(3-A)-Ala-Ala(3-A)-OEt.3HCl, and Ala(3-A)-Ala(3-A)-Ala(3-A)-OEt.4HCl were prepd. by std. active ester and dicyclohexylcarbodiimide peptide coupling reactions.

IT **58328-53-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 58328-53-3 CAPLUS

CN Alanine, 3-(6-amino-9H-pyrimidin-9-yl)-N-[N-[3-(6-amino-9H-pyrimidin-9-yl)-N-[(1,1-dimethylethoxy)carbonyl]alanyl]-L-alanyl]-, ethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2002 ACS

1974:515149 Document No. 81:115149 Puromycin analogs. Ribosomal binding with diastereomeric carbocyclic puromycin analogs. Vince, Robert; Daluge, Susan (Coll. Pharm., Univ. Minnesota, Minneapolis, Minn., USA). J. Med. Chem., 17(6), 578-83 (English) 1974. CODEN: JMCMAR.

AB Of 7 title compds. prepd. and found active in the inhibition of poly-UC-directed polyphenylalanine formation in an Escherichia coli cell-free system, 6-(dimethylamino)-9-[(R)-[(2R)-hydroxy-(3R)-(L-phenylalanyl)amino]]cyclopentyl]purine (I) [52661-26-4] gave 98.6% inhibition at 10⁻⁴M. I was prepd. from 3-acetamidocyclopentene

[52661-16-2] by epoxidn., opening of the epoxide with NaN₃ [26628-22-8], followed by redn. to the azido alc., resoln. via tartrate formation, introduction of the purine moiety, and coupling with the amino acid. The relation of structure of the various aminoacyl analogs to activity was discussed.


IT 52691-29-9

RL: RCT (Reactant)
(hydrogenolysis of)

RN 52691-29-9 CAPLUS

CN Carbamic acid, [1-[[[3-[6-(dimethylamino)-9H-purin-9-yl]-2-hydroxycyclopentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, [1S-[1.alpha.(R*),2.alpha.,3.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 52661-25-3P

RL: PREP (Preparation)
(prepn. of)

RN 52661-25-3 CAPLUS

CN Carbamic acid, [1-[[[3-[6-(dimethylamino)-9H-purin-9-yl]-2-hydroxycyclopentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, [1R-[1.alpha.(S*),2.alpha.,3.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L32 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2002 ACS

1974:34682 Document No. 80:34682 Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. XVII. L-Phenylalanine esters of open-chain analog of adenosine as substrates for ribosomal peptidyl transferase. Chladek, Stanislav; Ringer, David; Zemlicka, Jiri (Michigan Cancer Found., Detroit, Mich., USA). Biochemistry, 12(25), 5135-8 (English) 1973. CODEN: BICHAW.

AB The chem. synthesis of the open-chain analogs of 2'-O-(L-phenylalanyl)adenosine (I) and 3'-O-(L-phenylalanyl)adenosine (II) and 2',3'-bis-O-(L-phenylalanyl)adenosine (III) is described. Compds. I and III were active in the release of N-Ac-Phe-tRNA catalyzed by ribosomes: at 0.1mM, compd. I released 8% and II, 12% and at 1mM, 40 and 50%, resp., of the amt. of AcPhe released by 2'(3')-O-(L-phenylalanyl)adenosine. The results indicate that peptidyltransferase requires the 3'-aminoacyl deriv.

Searched by: Mary Hale 308-4258 CM-1 12D16


and that an intact furanose ring is of importance for the peptide transfer reaction.

IT 51034-62-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 51034-62-9 CAPLUS

CN L-Phenylalanine, N-[(phenylmethoxy)carbonyl]-, 2-[1-(6-amino-9H-purin-9-yl)-2-hydroxyethoxy]-3-hydroxypropyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)



L32 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2002 ACS

1971:112423 Document No. 74:112423 Nucleoside peptides. I. Synthesis of 5'-deoxy-5'-amino-5'-N-aminoacyl peptide derivatives of guanosine, adenosine, and 2'-deoxyadenosine and their effect of cell-free protein synthesis. Robins, Morris J.; Simon, Lionel N.; Stout, Mason G.; Ivanovics, George A.; Schweizer, Martin P.; Rousseau, Robert J.; Robins, Roland K. (ICN Nucl. Acid Res. Inst., Irvine, Calif., USA). J. Amer. Chem. Soc., 93(6), 1474-80 (English) 1971. CODEN: JACSAT.

AB Several 5'-N-aminoacyl-5'-amino-5'-deoxy- and 5'-amino-2',5'-dideoxy-9-.beta.-D-ribofuranosylpurine nucleoside peptides were synthesized which represent a new class of peptides were coupled to the corresponding purine 5'-amino-5'-deoxynucleoside deriv. by the active ester and dicyclohexylcarbodi-imide methods of peptide formation. These compds. were studied to det. their effect on poly-U directed polyphenylalanine synthesis. In instances where the aminoacyl moiety was L-phenylalanine and the nucleoside was either 5'-amino-5'-deoxyadenosine or 5'-amino-2',5'-dideoxyadenosine, inhibition of poly-U directed polyphenylalanine synthesis was obsd. at high concns. and significant stimulation was obsd. at lower concns. Chem. and biol. properties of this new type of nucleoside peptide are discussed. PMR data indicate that 5'-N-(L-phenylalanyl)-5'-amino-2',5'-dideoxyadenosine exists in soln. in a folded conformation with Ph and adenine ring stacking.


IT 31518-49-7P 31518-53-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 31518-49-7 CAPLUS


CN Adenosine, 5'-[2-(carboxyamino)-4-methylvaleramido]-2',5'-dideoxy-, benzyl ester, L- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 31518-53-3 CAPLUS
 CN Adenosine, 5'-[2-(carboxyamino)acetamido]-2',5'-dideoxy-, benzyl ester
 (8CI) (CA INDEX NAME)

Absolute stereochemistry.



COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	108.39	2344.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-15.49	-167.89

FILE 'CAOLD' ENTERED AT 13:09:45 ON 02 MAY 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for

Searched by: Mary Hale 308-4258 CM-1 12D16

more information.

L33 0 L31

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.38

2344.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-167.89

STN INTERNATIONAL LOGOFF AT 13:09:53 ON 02 MAY 2002